CA1212602A - Assay for analysis of whole blood - Google Patents
Assay for analysis of whole bloodInfo
- Publication number
- CA1212602A CA1212602A CA000445619A CA445619A CA1212602A CA 1212602 A CA1212602 A CA 1212602A CA 000445619 A CA000445619 A CA 000445619A CA 445619 A CA445619 A CA 445619A CA 1212602 A CA1212602 A CA 1212602A
- Authority
- CA
- Canada
- Prior art keywords
- whole blood
- reagent
- particles
- analyte
- zone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 89
- 239000008280 blood Substances 0.000 title claims abstract description 89
- 238000003556 assay Methods 0.000 title abstract description 53
- 238000004458 analytical method Methods 0.000 title abstract description 15
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 61
- 230000007480 spreading Effects 0.000 claims abstract description 54
- 238000003892 spreading Methods 0.000 claims abstract description 54
- 239000000203 mixture Substances 0.000 claims abstract description 48
- 239000012491 analyte Substances 0.000 claims abstract description 43
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 37
- 239000008103 glucose Substances 0.000 claims abstract description 37
- 230000002452 interceptive effect Effects 0.000 claims abstract description 29
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 22
- 239000012530 fluid Substances 0.000 claims abstract description 18
- 239000011148 porous material Substances 0.000 claims abstract description 17
- 239000011800 void material Substances 0.000 claims abstract description 16
- 230000003993 interaction Effects 0.000 claims abstract description 14
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 11
- 239000002245 particle Substances 0.000 claims description 63
- 238000000034 method Methods 0.000 claims description 36
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 claims description 28
- 239000000178 monomer Substances 0.000 claims description 28
- 229920000642 polymer Polymers 0.000 claims description 26
- 239000000853 adhesive Substances 0.000 claims description 23
- 230000001070 adhesive effect Effects 0.000 claims description 23
- 239000000463 material Substances 0.000 claims description 20
- -1 toluidine compound Chemical class 0.000 claims description 19
- 239000000126 substance Substances 0.000 claims description 12
- 230000003617 peroxidasic effect Effects 0.000 claims description 11
- 229920002554 vinyl polymer Polymers 0.000 claims description 10
- 102000003992 Peroxidases Human genes 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- 230000001427 coherent effect Effects 0.000 claims description 6
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 6
- 108010015776 Glucose oxidase Proteins 0.000 claims description 5
- 239000004366 Glucose oxidase Substances 0.000 claims description 5
- 229940116332 glucose oxidase Drugs 0.000 claims description 5
- 235000019420 glucose oxidase Nutrition 0.000 claims description 5
- FWEOQOXTVHGIFQ-UHFFFAOYSA-N 8-anilinonaphthalene-1-sulfonic acid Chemical compound C=12C(S(=O)(=O)O)=CC=CC2=CC=CC=1NC1=CC=CC=C1 FWEOQOXTVHGIFQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000002657 fibrous material Substances 0.000 claims description 4
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 3
- 150000002734 metacrylic acid derivatives Chemical class 0.000 claims description 3
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 claims description 3
- 125000005397 methacrylic acid ester group Chemical group 0.000 claims description 3
- 229920000620 organic polymer Polymers 0.000 claims description 3
- MHHJQVRGRPHIMR-UHFFFAOYSA-N 1-phenylprop-2-en-1-ol Chemical compound C=CC(O)C1=CC=CC=C1 MHHJQVRGRPHIMR-UHFFFAOYSA-N 0.000 claims description 2
- DUHQIGLHYXLKAE-UHFFFAOYSA-N 3,3-dimethylglutaric acid Chemical compound OC(=O)CC(C)(C)CC(O)=O DUHQIGLHYXLKAE-UHFFFAOYSA-N 0.000 claims description 2
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000005396 acrylic acid ester group Chemical group 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 150000002825 nitriles Chemical class 0.000 claims description 2
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 2
- OSSNTDFYBPYIEC-UHFFFAOYSA-N 1-ethenylimidazole Chemical compound C=CN1C=CN=C1 OSSNTDFYBPYIEC-UHFFFAOYSA-N 0.000 claims 1
- 229920000536 2-Acrylamido-2-methylpropane sulfonic acid Polymers 0.000 claims 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical group CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- 125000005250 alkyl acrylate group Chemical group 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 150000002978 peroxides Chemical group 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract description 5
- 239000000975 dye Substances 0.000 description 31
- 239000010410 layer Substances 0.000 description 27
- 239000000306 component Substances 0.000 description 19
- 150000001875 compounds Chemical class 0.000 description 14
- 150000002500 ions Chemical class 0.000 description 9
- 210000002381 plasma Anatomy 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 230000008901 benefit Effects 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 150000004992 toluidines Chemical class 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229940039227 diagnostic agent Drugs 0.000 description 3
- 239000000032 diagnostic agent Substances 0.000 description 3
- 239000011236 particulate material Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- CBQYNPHHHJTCJS-UHFFFAOYSA-N Alline Chemical compound C1=CC=C2C3(O)CCN(C)C3NC2=C1 CBQYNPHHHJTCJS-UHFFFAOYSA-N 0.000 description 2
- 108010089254 Cholesterol oxidase Proteins 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 101100345589 Mus musculus Mical1 gene Proteins 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000002998 adhesive polymer Substances 0.000 description 2
- 150000001448 anilines Chemical class 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000009477 glass transition Effects 0.000 description 2
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- OIPPWFOQEKKFEE-UHFFFAOYSA-N orcinol Chemical compound CC1=CC(O)=CC(O)=C1 OIPPWFOQEKKFEE-UHFFFAOYSA-N 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 239000004848 polyfunctional curative Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000000379 polymerizing effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000013389 whole blood assay Methods 0.000 description 2
- CBCKQZAAMUWICA-UHFFFAOYSA-N 1,4-phenylenediamine Chemical compound NC1=CC=C(N)C=C1 CBCKQZAAMUWICA-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical class NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 description 1
- KQQQHTFGBIWLOD-UHFFFAOYSA-N 3-(3-methylanilino)propanoic acid Chemical compound CC1=CC=CC(NCCC(O)=O)=C1 KQQQHTFGBIWLOD-UHFFFAOYSA-N 0.000 description 1
- VPWNQTHUCYMVMZ-UHFFFAOYSA-N 4,4'-sulfonyldiphenol Chemical class C1=CC(O)=CC=C1S(=O)(=O)C1=CC=C(O)C=C1 VPWNQTHUCYMVMZ-UHFFFAOYSA-N 0.000 description 1
- USGNZHHNWYDCTC-UHFFFAOYSA-N 4-amino-1,4-dihydropyrazol-5-one Chemical class NC1C=NNC1=O USGNZHHNWYDCTC-UHFFFAOYSA-N 0.000 description 1
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical class NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 1
- LLLVZDVNHNWSDS-UHFFFAOYSA-N 4-methylidene-3,5-dioxabicyclo[5.2.2]undeca-1(9),7,10-triene-2,6-dione Chemical compound C1(C2=CC=C(C(=O)OC(=C)O1)C=C2)=O LLLVZDVNHNWSDS-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 229930185605 Bisphenol Natural products 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 238000008620 Cholesterol Assay Methods 0.000 description 1
- 241000518994 Conta Species 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000490229 Eucephalus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 241001082241 Lythrum hyssopifolia Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 240000001987 Pyrus communis Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000000019 Sterol Esterase Human genes 0.000 description 1
- 108010055297 Sterol Esterase Proteins 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 150000003926 acrylamides Chemical class 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 150000001896 cresols Chemical class 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000003366 endpoint assay Methods 0.000 description 1
- 239000003248 enzyme activator Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960001867 guaiacol Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- ZUVBIBLYOCVYJU-UHFFFAOYSA-N naphthalene-1,7-diol Chemical compound C1=CC=C(O)C2=CC(O)=CC=C21 ZUVBIBLYOCVYJU-UHFFFAOYSA-N 0.000 description 1
- 150000004780 naphthols Chemical class 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920003213 poly(N-isopropyl acrylamide) Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000001055 reflectance spectroscopy Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000002235 transmission spectroscopy Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 238000007704 wet chemistry method Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
- G01N33/525—Multi-layer analytical elements
- G01N33/526—Multi-layer analytical elements the element being adapted for a specific analyte
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/805—Test papers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y10S436/81—Tube, bottle, or dipstick
Abstract
ASSAY FOR ANALYSIS OF WHOLE BLOOD
Abstract of the Disclosure Disclosed herein is an assay useful for the determination of an analyte in whole blood. In particular, this assay is useful for the quantitative determination of peroxide-generating analytes, such as glucose or cholesterol, in whole blood. This assay utilizes a multizone element consisting essentially of a support having thereon, in order and in fluid contact, a registration zone and a reagent/spreading zone. The reagent/spreading zone has a void volume and average pore size effective to accomodate whole blood, and contains an interactive composition necessary for the analysis. Such composition is capable of providing, upon interaction with the analyte, a dye which can be spectrophotometrically detected at a wavelength greater than about 600 nm.
Abstract of the Disclosure Disclosed herein is an assay useful for the determination of an analyte in whole blood. In particular, this assay is useful for the quantitative determination of peroxide-generating analytes, such as glucose or cholesterol, in whole blood. This assay utilizes a multizone element consisting essentially of a support having thereon, in order and in fluid contact, a registration zone and a reagent/spreading zone. The reagent/spreading zone has a void volume and average pore size effective to accomodate whole blood, and contains an interactive composition necessary for the analysis. Such composition is capable of providing, upon interaction with the analyte, a dye which can be spectrophotometrically detected at a wavelength greater than about 600 nm.
Description
~2~ 0~
ASSAY FOR ANALYSIS OF WHOLE BLOOD
FIELD OF THE INVENTION
The present invention relates to a "dry 5 chemistry" assay for whole blood. In partlcular, it relates ~o an assay useful for the quantitative determination of peroxide-generating analytes, e.g.
glucose or cholesterol, in whole blood. This invention also relates to multizone elements useful lo in such an assay.
BACKGROUND OF THE INVENTION
In order to provide desired preventative or dia~nostic health care, a physician must often determine the level of various analytes in a 15 patient's blood. For example, the level of glucose or cholesterol in the blood is often important in effe~tive treatment of various diseases, e.g.
diabetes, hypoglycemia, liver and thyroid disorders and atherosclerosis.
2Q Gener~lly, such analytes are measured in blood serum or plasma after the whole red blood cells have been removed. However, it would be desirable to be able to measure analytes in undiluted whale blood, thereby avoiding procedures required for separating 25 red blood cells from the rest of the fluid and attendant labor and equipmen~ costs. Using undiluted whole blood in analyses would also allow for simpler and aster sample procurement and processing. This would be especially usef~l for home monitoring assays 30 where~n the assay procedure should be as simple as possible.
"Dry chemistry" assays are known. Such assays are analytical cl~nical techniques wherein chemical reagents are ~ncorporated in various 35 substantially ~Idry to-the-~ouch" elements, e.g. test strips and multlzone analytical elements. The advantages of "dry chemistry~' assay5 over "wet chemistry" assays (i.e. techn~ques using reagents in solutions) are also known and include simpliclty of use, economic savings ~nd rapid snalysis. However, analysis of whole blood using dry chemistry assays 5 must overcome a serious problem. The corpuscul~r (red and white cells) and other high molecular weight components of whole blood must either be removed from the sample or somehow accommodated by the element ln order to provide an accurate assay. State-of-the-art o dry assays require removal of corpuscular components by allowing serum or plasma to penetrate an element and wiping of the corpuscular components which are unable to penetrate. Alternatlvely, for an element to accommodate the components, the void volume snd 15 pore size within the surace contacted by a blood sample must be sufficient to completely absorb the sample without clogging the analytical elementO At the same time, the pore structure must not be so large as to cause mech~nical instability ~i.e.
20 disintegration or fragmentation) of the element.
~ his problem is recognized in U. S. Patent 4,312,834 (issued January 26~ 1982 to Vogel et al) wherein a monolayer dlagnostic agent for analysis of fluids iB diselosed. This diagnostic agent comprises 25 a ~ilm forming ~aterial having a film opener therein to provide porosity. When the diagnostic agent ~s to be used for the detection of high molecular weight and corpuscular materials, the ratio of fil~ opener to film former ~ 8 higher than when low molecular 30 weight materials are to be detected. However, the diagnostic agent taught by this reference has insufficiellt porosity to absorb whole blood cells as seen in Exampl~s 4 and 5 wherein residual blood was wiped off ~he agent a~ter 1 minute reaction time and 35 prior to spectrophotometric measurement. Th2 practice of wiping off residual corpuscular components prior to quantitative measurement of an ~Zl;i~G02 analyte is common to commerclally-available whole blood elements or diagnostlc agents ~see, e.g. U. K.
Patent 911,181, published November 21, 1962).
Whole blood can also be assayed with an 5 element which has a porous outer spreading layer which ac~s as a filter to trap the large corpuscular components of whole blood whlle allowing the serum or plasma to pass through to a separate reagent layer, which layer contains the neceæsary reagents for o causing a detectable change to occur in ~he presence of a particular analyte. This technique is illustrated, or example, in Column 25 o U. S.
Patent 4,144,306 (issued March 13, 1979 to ~igueras~, Example 4 of U. S. Patent 4,258,001 ~issued Mar~h 24, 15 1981 to Pierce et al3, Example 3 of U. S. Patent 4,292,272 (i~sued Sep~ember 29, 1981 to K~ta~ima et al) and Example 2 of Japanese Patent Publica~ion 5~-101760 (published June ~4, 1982).
However, it would be advsntageous to avoid 20 the need to 6eparate the serum or plasma from corpuscular components in w~ole blood~ This procedure of filtering the components from the serum or plasma usin~ a filter layer is a ~low process.
There is also the likelihood thst a portion of the 25 analyte is lost in the filter/spreadlng layer as the plasma or serum passes through it, ~hereby resulting in an ~nQCcurate analysis.
U. S. Patent 4,042,335 ~issued August 16, 1977 to Clément) describes a whole blood assay 30 utilizing a multilayer analytical element. The described whole blood element comprises a support having thereon, in order, a registration l~yer, a radiation-blocking layer and a reagent layer. The reagent layer can act as a porous spreading layer 35 while the radiation-blocking layer can act as a filter layer ~o filter out and exclude whole blood cells from the regis~ration layer ~see FIG. 1 of the
ASSAY FOR ANALYSIS OF WHOLE BLOOD
FIELD OF THE INVENTION
The present invention relates to a "dry 5 chemistry" assay for whole blood. In partlcular, it relates ~o an assay useful for the quantitative determination of peroxide-generating analytes, e.g.
glucose or cholesterol, in whole blood. This invention also relates to multizone elements useful lo in such an assay.
BACKGROUND OF THE INVENTION
In order to provide desired preventative or dia~nostic health care, a physician must often determine the level of various analytes in a 15 patient's blood. For example, the level of glucose or cholesterol in the blood is often important in effe~tive treatment of various diseases, e.g.
diabetes, hypoglycemia, liver and thyroid disorders and atherosclerosis.
2Q Gener~lly, such analytes are measured in blood serum or plasma after the whole red blood cells have been removed. However, it would be desirable to be able to measure analytes in undiluted whale blood, thereby avoiding procedures required for separating 25 red blood cells from the rest of the fluid and attendant labor and equipmen~ costs. Using undiluted whole blood in analyses would also allow for simpler and aster sample procurement and processing. This would be especially usef~l for home monitoring assays 30 where~n the assay procedure should be as simple as possible.
"Dry chemistry" assays are known. Such assays are analytical cl~nical techniques wherein chemical reagents are ~ncorporated in various 35 substantially ~Idry to-the-~ouch" elements, e.g. test strips and multlzone analytical elements. The advantages of "dry chemistry~' assay5 over "wet chemistry" assays (i.e. techn~ques using reagents in solutions) are also known and include simpliclty of use, economic savings ~nd rapid snalysis. However, analysis of whole blood using dry chemistry assays 5 must overcome a serious problem. The corpuscul~r (red and white cells) and other high molecular weight components of whole blood must either be removed from the sample or somehow accommodated by the element ln order to provide an accurate assay. State-of-the-art o dry assays require removal of corpuscular components by allowing serum or plasma to penetrate an element and wiping of the corpuscular components which are unable to penetrate. Alternatlvely, for an element to accommodate the components, the void volume snd 15 pore size within the surace contacted by a blood sample must be sufficient to completely absorb the sample without clogging the analytical elementO At the same time, the pore structure must not be so large as to cause mech~nical instability ~i.e.
20 disintegration or fragmentation) of the element.
~ his problem is recognized in U. S. Patent 4,312,834 (issued January 26~ 1982 to Vogel et al) wherein a monolayer dlagnostic agent for analysis of fluids iB diselosed. This diagnostic agent comprises 25 a ~ilm forming ~aterial having a film opener therein to provide porosity. When the diagnostic agent ~s to be used for the detection of high molecular weight and corpuscular materials, the ratio of fil~ opener to film former ~ 8 higher than when low molecular 30 weight materials are to be detected. However, the diagnostic agent taught by this reference has insufficiellt porosity to absorb whole blood cells as seen in Exampl~s 4 and 5 wherein residual blood was wiped off ~he agent a~ter 1 minute reaction time and 35 prior to spectrophotometric measurement. Th2 practice of wiping off residual corpuscular components prior to quantitative measurement of an ~Zl;i~G02 analyte is common to commerclally-available whole blood elements or diagnostlc agents ~see, e.g. U. K.
Patent 911,181, published November 21, 1962).
Whole blood can also be assayed with an 5 element which has a porous outer spreading layer which ac~s as a filter to trap the large corpuscular components of whole blood whlle allowing the serum or plasma to pass through to a separate reagent layer, which layer contains the neceæsary reagents for o causing a detectable change to occur in ~he presence of a particular analyte. This technique is illustrated, or example, in Column 25 o U. S.
Patent 4,144,306 (issued March 13, 1979 to ~igueras~, Example 4 of U. S. Patent 4,258,001 ~issued Mar~h 24, 15 1981 to Pierce et al3, Example 3 of U. S. Patent 4,292,272 (i~sued Sep~ember 29, 1981 to K~ta~ima et al) and Example 2 of Japanese Patent Publica~ion 5~-101760 (published June ~4, 1982).
However, it would be advsntageous to avoid 20 the need to 6eparate the serum or plasma from corpuscular components in w~ole blood~ This procedure of filtering the components from the serum or plasma usin~ a filter layer is a ~low process.
There is also the likelihood thst a portion of the 25 analyte is lost in the filter/spreadlng layer as the plasma or serum passes through it, ~hereby resulting in an ~nQCcurate analysis.
U. S. Patent 4,042,335 ~issued August 16, 1977 to Clément) describes a whole blood assay 30 utilizing a multilayer analytical element. The described whole blood element comprises a support having thereon, in order, a registration l~yer, a radiation-blocking layer and a reagent layer. The reagent layer can act as a porous spreading layer 35 while the radiation-blocking layer can act as a filter layer ~o filter out and exclude whole blood cells from the regis~ration layer ~see FIG. 1 of the
2 ~
reference), thereby avoiding interference by hemoglobin.
While such an element may be use~d to determine an analyte in whole blood, its usefulness 5 depends to a large degree on having a detectable species which can rapidly diffuse through the radiation-blocking layer ~o the registration layer and which has a sufficiently high extinction coefficient. However, not all detectable species 10 (e-g- dyes, color-forming couplers, etc.~ satixfy these requirements.
Hence, it would be desirable to have a simple and rapid "dry chemistry" assay ~or undiluted whole blood which provides rapid and accurate 15 analysis and eliminates the need to wipe o~f residual blood.
SUMMARY OF THE INVENTION
The present invention provides a "dry chemistry" assay useful for determination of an 20 analyte in undiluted whole blood. This assay overcomes the problems associated with known whole blood assays. Nsmely, lt is slmple, rapid~ accurate and can be used to analyze und~luted whole blood samples. The assay of th~s invention obvlates the 25 need to wipe o~f excess blood (i.e. corpuscular components) or to dilute the blood sampls. Further~
it makes separation of the cellular components of the blood from the plasma or serum unnecessary, and eliminates the need for separate radiatlon-30 blocking/filter layers. Interference by hemoglobini5 not a concern with the sssay of this invention because the dye provided in the inter~c~ion with the analyte is spectrophotometrically detectable at a wavelength greater than about 600 nm. Surpr~singly, 35 the assay of this inventlon is also extremely rapid, i.e. it generally provides analysis in 2 or 3 minutes or less. Another unexpected adv~ntage provided by this assay is its insensitivity to fluc~uations in hematocrit and hemoglobln values from sample to sample.
Therefore, in accordance wlth this 5 invention, a method for the determination o~ an analyte in whole blood comprises the steps of:
(A) physically contacting a sample o~ whole blood and a multizone element, whlch ~lement consists essentially of a support having thereon, ~n order and 0 iII fluid contact, a registration zone and a reagent/spreading zone, the reagent/spreading zone having a void volume and average pore size e~fective to accommodate whole blood, and contalning an 5 interactive composition capable of provlding, upon interaction with the analyte, a dye which can be spectrophotometrically detected at a wavelength greater than about 600 nm; and ~B3 detecting such dye at a wavelength 20 greater than about 600 nm.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a graphical plot of reflectance density measured at 660 nm vs. time (min.~ for assays of undiluted whole blood samples containing various 25 amounts of glucose det~rmined according to this ~nvention~
FIGS. 2 and 3 are graphical plots of reflectance density measured at 565 nm vs. time (min.) for assays of undiluted whole blood samples 30 containing various amounts o glucose determined according to the teaching of the prior art.
FIG. 4 is a graphical plot simllar to FIG. 1 except that the glucose assay was carried out using another color-forming coupler.
FIG. 5 is a gr~phical plot similar to FIG. 4 except that the glucose assay was carried out according to the teaching of the prior art.
2 ~
FIG. 6 is a graphical plot of optical density (Dr) measured at 630 nm vs. eholesterol concentration (mg/dL) for ass~ys of undilu~ed whole blood samples contalning various amounts of 5 cholesterol determined according to this invention.
DETAILED DESCRIPTION OF THE INVENTION
The assay of this invention i5 useful for the quantltative determination of an analyte ~n whole blood. For example, the assay of this invention can o also be used as an immunoassay with a par~iculsr antigen considered the analyte to be determined.
This assay is partlcularly useful for determining peroxide-generating analytes, such as glucose, cholesterol, uric acid, glycerol, triglycerldes, 5 etc. Preferably, this invention is used for quantitative analysis of glucose or cholesterol, and most preferably, of glucose.
The assay of this inven~ion is sui~able for analysis of whole blood, diluted or undlluted. But 20 one of ~ts advantages is its capability for analyz~ng undiluted whole blood~ By 'lundiluted" whole blood is meant whole blood which has not been thinned w~th saline solution, serum, plasma, etc. The advantages obtained with the assay of this inventlon are 25 possible with the use of a multizone element which has two essential zones, a spreading/reagent zone which can accommodate, or absorb, a whole blood sample (e.g. 5-20 ~L) without the need to wipe off excess blood~ and a registration zone to which dye 30 formed in reæponse to the presence o~ an analyte migrates.
Generally, in order to accommodate an ~ndiluted whole blood sample, the void volume ln the reagent/spreading layer is ln the range o from about 35 25 to about 80 percent depending upon the materials used~ and preferably from about 40 to about 60 percent. The average pore size is generally at lea~t ~;26~a~
5 microns, and more likely from about 15 to about 65 microns depending upon the materials used.
The reagent/spreading zone can be prepared from any suitable fibrous or non-fibrous material or mixtures thereof as long as the zone can accommodate whole blood with the appropriate void volume and average pore size. The reagent/spreading zone advan-tageously produces a uniform concentration of whole blood per unit area at its surface facing the regis-tration zone with which the reagent/spreading zone is in fluid contact. Such uniformi~y of concentration can be determined by densitometrir or other analyti-cal techniques known in the art~
Useful reagent/spreading zones cfln be prepared using fibrous materials, either mixed with a suitable binder material or woven into a fabric~
as described in U. S. Patent 4,292,272 (issued September 29, 1981 to Kitajima et al). Alterna-tively, the zones are isotropically porous and can be prepared using polymeric compositions (e.g~ blush polymers), according to the teaching of U. S. Patent
reference), thereby avoiding interference by hemoglobin.
While such an element may be use~d to determine an analyte in whole blood, its usefulness 5 depends to a large degree on having a detectable species which can rapidly diffuse through the radiation-blocking layer ~o the registration layer and which has a sufficiently high extinction coefficient. However, not all detectable species 10 (e-g- dyes, color-forming couplers, etc.~ satixfy these requirements.
Hence, it would be desirable to have a simple and rapid "dry chemistry" assay ~or undiluted whole blood which provides rapid and accurate 15 analysis and eliminates the need to wipe o~f residual blood.
SUMMARY OF THE INVENTION
The present invention provides a "dry chemistry" assay useful for determination of an 20 analyte in undiluted whole blood. This assay overcomes the problems associated with known whole blood assays. Nsmely, lt is slmple, rapid~ accurate and can be used to analyze und~luted whole blood samples. The assay of th~s invention obvlates the 25 need to wipe o~f excess blood (i.e. corpuscular components) or to dilute the blood sampls. Further~
it makes separation of the cellular components of the blood from the plasma or serum unnecessary, and eliminates the need for separate radiatlon-30 blocking/filter layers. Interference by hemoglobini5 not a concern with the sssay of this invention because the dye provided in the inter~c~ion with the analyte is spectrophotometrically detectable at a wavelength greater than about 600 nm. Surpr~singly, 35 the assay of this inventlon is also extremely rapid, i.e. it generally provides analysis in 2 or 3 minutes or less. Another unexpected adv~ntage provided by this assay is its insensitivity to fluc~uations in hematocrit and hemoglobln values from sample to sample.
Therefore, in accordance wlth this 5 invention, a method for the determination o~ an analyte in whole blood comprises the steps of:
(A) physically contacting a sample o~ whole blood and a multizone element, whlch ~lement consists essentially of a support having thereon, ~n order and 0 iII fluid contact, a registration zone and a reagent/spreading zone, the reagent/spreading zone having a void volume and average pore size e~fective to accommodate whole blood, and contalning an 5 interactive composition capable of provlding, upon interaction with the analyte, a dye which can be spectrophotometrically detected at a wavelength greater than about 600 nm; and ~B3 detecting such dye at a wavelength 20 greater than about 600 nm.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a graphical plot of reflectance density measured at 660 nm vs. time (min.~ for assays of undiluted whole blood samples containing various 25 amounts of glucose det~rmined according to this ~nvention~
FIGS. 2 and 3 are graphical plots of reflectance density measured at 565 nm vs. time (min.) for assays of undiluted whole blood samples 30 containing various amounts o glucose determined according to the teaching of the prior art.
FIG. 4 is a graphical plot simllar to FIG. 1 except that the glucose assay was carried out using another color-forming coupler.
FIG. 5 is a gr~phical plot similar to FIG. 4 except that the glucose assay was carried out according to the teaching of the prior art.
2 ~
FIG. 6 is a graphical plot of optical density (Dr) measured at 630 nm vs. eholesterol concentration (mg/dL) for ass~ys of undilu~ed whole blood samples contalning various amounts of 5 cholesterol determined according to this invention.
DETAILED DESCRIPTION OF THE INVENTION
The assay of this invention i5 useful for the quantltative determination of an analyte ~n whole blood. For example, the assay of this invention can o also be used as an immunoassay with a par~iculsr antigen considered the analyte to be determined.
This assay is partlcularly useful for determining peroxide-generating analytes, such as glucose, cholesterol, uric acid, glycerol, triglycerldes, 5 etc. Preferably, this invention is used for quantitative analysis of glucose or cholesterol, and most preferably, of glucose.
The assay of this inven~ion is sui~able for analysis of whole blood, diluted or undlluted. But 20 one of ~ts advantages is its capability for analyz~ng undiluted whole blood~ By 'lundiluted" whole blood is meant whole blood which has not been thinned w~th saline solution, serum, plasma, etc. The advantages obtained with the assay of this inventlon are 25 possible with the use of a multizone element which has two essential zones, a spreading/reagent zone which can accommodate, or absorb, a whole blood sample (e.g. 5-20 ~L) without the need to wipe off excess blood~ and a registration zone to which dye 30 formed in reæponse to the presence o~ an analyte migrates.
Generally, in order to accommodate an ~ndiluted whole blood sample, the void volume ln the reagent/spreading layer is ln the range o from about 35 25 to about 80 percent depending upon the materials used~ and preferably from about 40 to about 60 percent. The average pore size is generally at lea~t ~;26~a~
5 microns, and more likely from about 15 to about 65 microns depending upon the materials used.
The reagent/spreading zone can be prepared from any suitable fibrous or non-fibrous material or mixtures thereof as long as the zone can accommodate whole blood with the appropriate void volume and average pore size. The reagent/spreading zone advan-tageously produces a uniform concentration of whole blood per unit area at its surface facing the regis-tration zone with which the reagent/spreading zone is in fluid contact. Such uniformi~y of concentration can be determined by densitometrir or other analyti-cal techniques known in the art~
Useful reagent/spreading zones cfln be prepared using fibrous materials, either mixed with a suitable binder material or woven into a fabric~
as described in U. S. Patent 4,292,272 (issued September 29, 1981 to Kitajima et al). Alterna-tively, the zones are isotropically porous and can be prepared using polymeric compositions (e.g~ blush polymers), according to the teaching of U. S. Patent
3,~92,158 (issued November 1~, 1976 to Przybylowicz et al).
Isotropically porous reagen~/spreading zones can also be prepared with particulate material where-ln the isotropic porosity ls created by intercon-nected spaces between the particles. Various types of particula~e matter, all desirably non-swellable in and chemically inert and impermeable to whole blood components, are useful including, for example, pig-ments ~e.g. titanium dioxide, barium sulfate, etc.), diatomaceous earth~ colloidal materials (e.g. micro-crys~alline cellulose), resinous or glass beads and the like. If a particulate material of choice is not .
~ -I
adherent, it can be treated to obtain particles that adhere to each other on surface areas of adjacent particles where those particles are in closest prox imity to form a coherent, three-dimensional lattice which is non-swellable in whole blood.
Examples of other useful particulate mate-rials include the polymer particles described in W.
German OLS 3,150,10~ (publ;shed July 29, 1982 and assigned to Konishiroku Photo), which particles are chemically bonded through reactive groups at the points of particle contact which reactive groups are incorporated in the particles; and the polymer par-ticles described in Japanese Patent Publication 57(1982)-101760 (published June 24, 1982 and assigned to Konishiroku Photo)~ which particles are chemically bonded at points of contact wi~h a low molecular weight adhesive compound (e.g. reaction products of bisphenols, dicarboxylic acids, and/or amino com-pounds, etc.).
Particu]arly useful reagent/spreading zones are those having a particulate structure formed by organo-polymeric particles and polymeric adhesive for those particles described in U. S. Patent 4~258,001 (issued March 24, 1981 to Pierce et al). The inter-connected voids among the adjacent particles of such a structure accommodate the corpuscular and high molecular weight components of whole blood and pro-vide for transport of analytes therein. Maintaining particulate lntegrlty of the organo-polymeric par-ticles in the particulate structure with a polymeric adhesive prevents the coalescence and flow of these materials into the voids, and the concentration of such adhesive at those particle surface areas of the structure which are contiguous to adjacent particles insures tha~ the adhesive does not flow in~o and clog the voids.
~ ~;
~.
6~2 The materials u~ed to prepare the reagent/spreading zone preferred in the prsctice of this invention are described in considerable detail in the Pierce et al patentO Since the de~ils and 5 definitions of the reagent/spreading zone are provided in that reference, the present d~sclosure is directed to a general description of the zone while noting preferred embodiments of this invention. The thickness of the described particulate struc~ure can lo be widely varied depending upon the size of the organo-polymeric particles and the specific analyte to be determined. However, the thickness i8 generally within the range of from about 10 to about 500 microns.
The heat-stable, organo-polymeric particles useful in the practice of this invention are generally spherical beads having a particle size in the range of from about 1 to about 200 microns.
Preferably, they have a substantially uni~o~m size 20 within the range of from about 20 to about 80 microns.
The particles can be composed o a wide variety of organlc polymers, including both natural and synthetic polymers, having the requisite properties. Preferably, however, they are composed 25 of one or more addition polymers ormed ~rom one or more ethylenically unsaturated polymeriæable monomers, such as addition homopolymers of single monomers or copolymer~ formed from two or more of such monomers. These polymers can be prepared by any 30 of a variety of conventional polymerization methods (e.g. solution, emulsion, dispersion, suspension, etc.). If desired, although the inven~ion is not so llmited, the particular polymer can contain one or more reaction sites to link various interac~ive 35 compositions to the particles.
~Z9~;~6~2 Particularly useful addition polymers are those formed by polymerizing one or more of the following ethylenically unsaturated polymerizable monomers, the details of which are provided in the 5 Pierce et al paten~ noted hereinabove:
(a) from 0 to 100, preferably from 0 to about 99, weight percent of one or more amino-substituent-free vinyl carbocyclic aromatic monomers, including the s~yrene monomers described in lo the Pierce et al patent, as well as similar amino-substituent-free vinyl naphthyl monomers;
(b) from 0 to about 25 weigh~ percent of one or more acrylic acid esters;
(c~ from 0 to 100, preferably 0 to ~bout 75, 15 weight percent of one or more methacrylic acid esters;
~d) from 0 to about 30 weight percent of one or more ethylenically unsaturated carboxylic acids;
(e) from 0 to about 75 weight percent of one or more ethylenically unsaturated nitrile;
(f) from 0 tc about 20 weight percent o one or more amino-sub~tituted vinyl carbocyclic aromatics 9 including the styrene monomers described in the Pierce et al patent, as well as B imilar amino substituted vinyl naphthyls;
(g) ~rom 0 to about 20, preferably 0 to about 10, weigh~ parcent o~ one or more ethylenically unsaturated crosslinkable monomeræ, including those which can be crosslinked with amines or gel~tin hardenere and those having two or more ethylenically 3Q unsaturated polymerizable groups;
(h) from 0 to about 20 weight percent of one or more ~ertiary aminoalkyl acrylates or methacrylates;
(i) from 0 to 100, preferably 0 to about 75, 35 weight percent of one or more polymerizable, N-heterocyclic vinyl monomer~; and ~IL2~
(~) from 0 to about 20 weight percent of one or more acrylamides or methacrylamides.
Particularly useful addition polymers include those listed ln Table I of ~he Pierce et al 5 patent. The numbers in the brackets represen~ the weight ratio of monomers in the monomer blPnd used to prepare ~he polymer. Poly(vinyltoluene-co-p-t-butyl-styrene-co-methacrylic acid) [61:37:2] is a preferred polymer. The organo-polymeric part~cles can contain lo other addenda, if des~red, as known in the art.
The polymeric adhesive which is useful in this invention bonds the organo-polymeric particles to one another to provide a coherent) three-dimensional lattice in ~he reagent/spreading 15 zone. The details of this adhesive are provided in the Pierce ~t al patent, noted hereinabove.
Generally, the adhesive ~s composed o an organic polymer different from the specific polymer contained ~n ~he particles, although quite commonly the 20 adhesive represents a polymer containing many repeating units which are identical or similar to some of ~hose present ln the polymer composi~ion of the pnrticles.
Preferably, the adhesive i8 composed of one 25 or more ~ddition polymers formed from one or more ethylen~cally unsaturated polymerizable monomers, such as addition copolymers formed from two or more of such monomers. Like ~he particles, the adhesive can be prepared by any of a variety o conventional 30 polymerization methods.
~enerally, the amount of adhesive contained in the particulate structure is less than about 10 percent~ and preferably from about 1 to about 5 percent, based on the weight of the particles.
Particularly useful addition polymers employed as adhesives are formed by polymerizing a blend of ethylenically unsaturated polymer~zable 12~Z6~2 12~
monomers selected from the blends described as follows, the details of which are provided in thè
Pierce et al patent noted hereinabove:
A. a blend containing from about 1 to about 5 35, preferably from about 10 to about 30, welght percent of one or more amino-substituent-free vinyl carbocyclic aroma~ics as described hereinabove, and from about 65 to about 99, preferably from about 70 to about 90, weight percent of one or more alkyl lo acrylates or methacrylates;
B. a blend containing from about 20 to about 95, preferably from about 50 to about 95, weight percent of one or more amino-substituen~ ~ree vinyl carbocyclic aromatics, acrylic or methacrylic acid 15 esters and ethylenically unsaturated polymerizable crosslinkable monomers, and from about 5 to about 8Q, pre~erably from about 5 to about 50, weight percent of one or more ethylenically unsaturated polymerizable monomers having an active hydrogen or 20 salts thereof; and C. a blend containing rom about 15 to 100 weight percent of one or more ethylenically unsaturated monomers selected from the group consisting of l-vinylimidazole, vinylbenzyl alcohol, 25 ethyl acrylate or an acrylamide or me~hacrylamide~
and from 0 to about 85 weight percent of one or more ethylenically unsaturat~d polymerizsble crosslinkable monomers.
Particularly useful addition polymers 30 include thos~ llsted in Table II of the Pierce et al patent. The numbers in ~he bracketæ represent ~he weight ratio of monomers in the monomer blend used to prepare the polymer. Poly(n-butyl acrylate-co-styrene-co-2-acrylamido-2-methylpropane sulfonic 35 acid) ~70:20:10~ is a preferred adhesive polymer.
2 ~
Generally, the adhesive polymer~ have a glass transition temperature (Tg) which is at least 20C, and preferably at least 30C, less than the Tg of the organo-polymer in the particles. Preferred 5 adhesives have a Tg below about 80C, and generally less than about 30C ~as measured under high relatlve humidlty conditions, i.e. > 80% R.H.). The term glass transition temperature is defined herein to be that temperature at which the polymer changes from a 1o glassy polymer to a rubbery or flowable polymer. The Tg can be measured in any suitable manner as described, for example, in "Techniques and Methods of Polymer Evaluation~" Vol. l, Marcel Dekker, Inc.
N. Y. (1966).
~arious methods can be employed for preparing the particulate structure with the above-described particles and adhesive. Specific details ~f useful methods are provided in the Pierce et al patent noted hereinaboYe.
The reagent/spreading zone of the described elements contains one or more interactive compositions. These rompositions compri~e one or more active components which undergo interaction with an analyte, or a reaction or decomposition product of 25 the analyte, or with each other upon physical contact of a sample of whole blood containing the analyte with the reagent/spreading zo~e. It ~e essential ~o the assay of this invention that such interaction provides a dye which can be ~pectrophotometrically 30 detected at a wavelength greater than about 600 nm, and preferably greater ~han about 630 nm. That isj such a dye must have a high enough extinc~ion so that significant optical density can be observed at a wavelength above about 600 nm, and preferably above 35 about 630 nm~ The dye can be provided either by interaction with a dye-providing material, or by dye release from a preformed dye The term "interactlon'7 ~Z~ 2 iB meant to refer to chemical activity, catalytic activity ~8 in the formation of an enzyme~sub6trate complex, immuno~enic activ~ty as in an antigen-antibody reaction, and any other form of 5 electrical, chem~cal or physical interaction ~hat can release, produce or otherwise provide the detectable dye, the concentration of which is directly or indirectly indicative of the presence or concentration of a particular analyte.
o Although not essential, the interactive composition can be immobilized in the partlculate structure of the reagent/spreading zone ~o minimize or prevent undesired migra~ion of the composition within the ~truc~ure or other zones of the element.
15 Immobilization can be accomplished by any suitable technique known to one of ordinary skill in ~he art.
Particular interactive compositions that can be distributed within the reagent/spreading zone depend upon the assay of choice. Particularly useful 20 interactive cQmpositions comprise a substance having peroxidative actlvity ~defined hereinbelow). In the case of many analyses, enzymes~ such 2S oxidase materials lik~ glucose 02idase or cholesterol oxidase, can desirably be included within the 25 reagent/spreadin~ zone for the analysis of the analyte that is a ~ubstra~e for such enzyme.
Generally, the interactive composition also includes a dye providing composition. Such compositions include a compound that~ when oxidized, 30 can couple within itself or with its reduced form to provide a dye. Such autocoupling compounds include a variety of hydroxylated compounds, such as o-aminophenols, 4-alkoxyn~phthols, 4-amino-5-pyrazolones, cresols, pyrogallol, guaiacol, orcinol, 35 cstechol, chloroglucinol, p-dihydroxydiphenylgallic acid, pyrocatechoic acid, and salicylic acid.
Compounds of this type are well known and describ2d ~2~lZBO~
in the literature, such as in The Theory of the Photographic Process, Mees and James, 3rd Edition, 1966, especially in Chapter 17.
As another example, the dye can be provided 5 by oxida~ion of a leuco dye compound. Representative leuco dyes include such subs~ances as triaryl-imidazole leuco dyes and other leuco dyes, as described in U. S. Patent 4,089,747 (~ssued May 16, 1978 to Bruschi) and triarylmethane leuco dyes as lo known in the art.
As yet another example, the dye iB formed by dye-providing compositions that include the condensation products of oxidizable compounds with couplers. Representative oxid~zable compounds 15 include benzidine and its homologs, p-phenyldiamine~, p-aminophenols 9 an aminoantipyrine, e.g.
Isotropically porous reagen~/spreading zones can also be prepared with particulate material where-ln the isotropic porosity ls created by intercon-nected spaces between the particles. Various types of particula~e matter, all desirably non-swellable in and chemically inert and impermeable to whole blood components, are useful including, for example, pig-ments ~e.g. titanium dioxide, barium sulfate, etc.), diatomaceous earth~ colloidal materials (e.g. micro-crys~alline cellulose), resinous or glass beads and the like. If a particulate material of choice is not .
~ -I
adherent, it can be treated to obtain particles that adhere to each other on surface areas of adjacent particles where those particles are in closest prox imity to form a coherent, three-dimensional lattice which is non-swellable in whole blood.
Examples of other useful particulate mate-rials include the polymer particles described in W.
German OLS 3,150,10~ (publ;shed July 29, 1982 and assigned to Konishiroku Photo), which particles are chemically bonded through reactive groups at the points of particle contact which reactive groups are incorporated in the particles; and the polymer par-ticles described in Japanese Patent Publication 57(1982)-101760 (published June 24, 1982 and assigned to Konishiroku Photo)~ which particles are chemically bonded at points of contact wi~h a low molecular weight adhesive compound (e.g. reaction products of bisphenols, dicarboxylic acids, and/or amino com-pounds, etc.).
Particu]arly useful reagent/spreading zones are those having a particulate structure formed by organo-polymeric particles and polymeric adhesive for those particles described in U. S. Patent 4~258,001 (issued March 24, 1981 to Pierce et al). The inter-connected voids among the adjacent particles of such a structure accommodate the corpuscular and high molecular weight components of whole blood and pro-vide for transport of analytes therein. Maintaining particulate lntegrlty of the organo-polymeric par-ticles in the particulate structure with a polymeric adhesive prevents the coalescence and flow of these materials into the voids, and the concentration of such adhesive at those particle surface areas of the structure which are contiguous to adjacent particles insures tha~ the adhesive does not flow in~o and clog the voids.
~ ~;
~.
6~2 The materials u~ed to prepare the reagent/spreading zone preferred in the prsctice of this invention are described in considerable detail in the Pierce et al patentO Since the de~ils and 5 definitions of the reagent/spreading zone are provided in that reference, the present d~sclosure is directed to a general description of the zone while noting preferred embodiments of this invention. The thickness of the described particulate struc~ure can lo be widely varied depending upon the size of the organo-polymeric particles and the specific analyte to be determined. However, the thickness i8 generally within the range of from about 10 to about 500 microns.
The heat-stable, organo-polymeric particles useful in the practice of this invention are generally spherical beads having a particle size in the range of from about 1 to about 200 microns.
Preferably, they have a substantially uni~o~m size 20 within the range of from about 20 to about 80 microns.
The particles can be composed o a wide variety of organlc polymers, including both natural and synthetic polymers, having the requisite properties. Preferably, however, they are composed 25 of one or more addition polymers ormed ~rom one or more ethylenically unsaturated polymeriæable monomers, such as addition homopolymers of single monomers or copolymer~ formed from two or more of such monomers. These polymers can be prepared by any 30 of a variety of conventional polymerization methods (e.g. solution, emulsion, dispersion, suspension, etc.). If desired, although the inven~ion is not so llmited, the particular polymer can contain one or more reaction sites to link various interac~ive 35 compositions to the particles.
~Z9~;~6~2 Particularly useful addition polymers are those formed by polymerizing one or more of the following ethylenically unsaturated polymerizable monomers, the details of which are provided in the 5 Pierce et al paten~ noted hereinabove:
(a) from 0 to 100, preferably from 0 to about 99, weight percent of one or more amino-substituent-free vinyl carbocyclic aromatic monomers, including the s~yrene monomers described in lo the Pierce et al patent, as well as similar amino-substituent-free vinyl naphthyl monomers;
(b) from 0 to about 25 weigh~ percent of one or more acrylic acid esters;
(c~ from 0 to 100, preferably 0 to ~bout 75, 15 weight percent of one or more methacrylic acid esters;
~d) from 0 to about 30 weight percent of one or more ethylenically unsaturated carboxylic acids;
(e) from 0 to about 75 weight percent of one or more ethylenically unsaturated nitrile;
(f) from 0 tc about 20 weight percent o one or more amino-sub~tituted vinyl carbocyclic aromatics 9 including the styrene monomers described in the Pierce et al patent, as well as B imilar amino substituted vinyl naphthyls;
(g) ~rom 0 to about 20, preferably 0 to about 10, weigh~ parcent o~ one or more ethylenically unsaturated crosslinkable monomeræ, including those which can be crosslinked with amines or gel~tin hardenere and those having two or more ethylenically 3Q unsaturated polymerizable groups;
(h) from 0 to about 20 weight percent of one or more ~ertiary aminoalkyl acrylates or methacrylates;
(i) from 0 to 100, preferably 0 to about 75, 35 weight percent of one or more polymerizable, N-heterocyclic vinyl monomer~; and ~IL2~
(~) from 0 to about 20 weight percent of one or more acrylamides or methacrylamides.
Particularly useful addition polymers include those listed ln Table I of ~he Pierce et al 5 patent. The numbers in the brackets represen~ the weight ratio of monomers in the monomer blPnd used to prepare ~he polymer. Poly(vinyltoluene-co-p-t-butyl-styrene-co-methacrylic acid) [61:37:2] is a preferred polymer. The organo-polymeric part~cles can contain lo other addenda, if des~red, as known in the art.
The polymeric adhesive which is useful in this invention bonds the organo-polymeric particles to one another to provide a coherent) three-dimensional lattice in ~he reagent/spreading 15 zone. The details of this adhesive are provided in the Pierce ~t al patent, noted hereinabove.
Generally, the adhesive ~s composed o an organic polymer different from the specific polymer contained ~n ~he particles, although quite commonly the 20 adhesive represents a polymer containing many repeating units which are identical or similar to some of ~hose present ln the polymer composi~ion of the pnrticles.
Preferably, the adhesive i8 composed of one 25 or more ~ddition polymers formed from one or more ethylen~cally unsaturated polymerizable monomers, such as addition copolymers formed from two or more of such monomers. Like ~he particles, the adhesive can be prepared by any of a variety o conventional 30 polymerization methods.
~enerally, the amount of adhesive contained in the particulate structure is less than about 10 percent~ and preferably from about 1 to about 5 percent, based on the weight of the particles.
Particularly useful addition polymers employed as adhesives are formed by polymerizing a blend of ethylenically unsaturated polymer~zable 12~Z6~2 12~
monomers selected from the blends described as follows, the details of which are provided in thè
Pierce et al patent noted hereinabove:
A. a blend containing from about 1 to about 5 35, preferably from about 10 to about 30, welght percent of one or more amino-substituent-free vinyl carbocyclic aroma~ics as described hereinabove, and from about 65 to about 99, preferably from about 70 to about 90, weight percent of one or more alkyl lo acrylates or methacrylates;
B. a blend containing from about 20 to about 95, preferably from about 50 to about 95, weight percent of one or more amino-substituen~ ~ree vinyl carbocyclic aromatics, acrylic or methacrylic acid 15 esters and ethylenically unsaturated polymerizable crosslinkable monomers, and from about 5 to about 8Q, pre~erably from about 5 to about 50, weight percent of one or more ethylenically unsaturated polymerizable monomers having an active hydrogen or 20 salts thereof; and C. a blend containing rom about 15 to 100 weight percent of one or more ethylenically unsaturated monomers selected from the group consisting of l-vinylimidazole, vinylbenzyl alcohol, 25 ethyl acrylate or an acrylamide or me~hacrylamide~
and from 0 to about 85 weight percent of one or more ethylenically unsaturat~d polymerizsble crosslinkable monomers.
Particularly useful addition polymers 30 include thos~ llsted in Table II of the Pierce et al patent. The numbers in ~he bracketæ represent ~he weight ratio of monomers in the monomer blend used to prepare the polymer. Poly(n-butyl acrylate-co-styrene-co-2-acrylamido-2-methylpropane sulfonic 35 acid) ~70:20:10~ is a preferred adhesive polymer.
2 ~
Generally, the adhesive polymer~ have a glass transition temperature (Tg) which is at least 20C, and preferably at least 30C, less than the Tg of the organo-polymer in the particles. Preferred 5 adhesives have a Tg below about 80C, and generally less than about 30C ~as measured under high relatlve humidlty conditions, i.e. > 80% R.H.). The term glass transition temperature is defined herein to be that temperature at which the polymer changes from a 1o glassy polymer to a rubbery or flowable polymer. The Tg can be measured in any suitable manner as described, for example, in "Techniques and Methods of Polymer Evaluation~" Vol. l, Marcel Dekker, Inc.
N. Y. (1966).
~arious methods can be employed for preparing the particulate structure with the above-described particles and adhesive. Specific details ~f useful methods are provided in the Pierce et al patent noted hereinaboYe.
The reagent/spreading zone of the described elements contains one or more interactive compositions. These rompositions compri~e one or more active components which undergo interaction with an analyte, or a reaction or decomposition product of 25 the analyte, or with each other upon physical contact of a sample of whole blood containing the analyte with the reagent/spreading zo~e. It ~e essential ~o the assay of this invention that such interaction provides a dye which can be ~pectrophotometrically 30 detected at a wavelength greater than about 600 nm, and preferably greater ~han about 630 nm. That isj such a dye must have a high enough extinc~ion so that significant optical density can be observed at a wavelength above about 600 nm, and preferably above 35 about 630 nm~ The dye can be provided either by interaction with a dye-providing material, or by dye release from a preformed dye The term "interactlon'7 ~Z~ 2 iB meant to refer to chemical activity, catalytic activity ~8 in the formation of an enzyme~sub6trate complex, immuno~enic activ~ty as in an antigen-antibody reaction, and any other form of 5 electrical, chem~cal or physical interaction ~hat can release, produce or otherwise provide the detectable dye, the concentration of which is directly or indirectly indicative of the presence or concentration of a particular analyte.
o Although not essential, the interactive composition can be immobilized in the partlculate structure of the reagent/spreading zone ~o minimize or prevent undesired migra~ion of the composition within the ~truc~ure or other zones of the element.
15 Immobilization can be accomplished by any suitable technique known to one of ordinary skill in ~he art.
Particular interactive compositions that can be distributed within the reagent/spreading zone depend upon the assay of choice. Particularly useful 20 interactive cQmpositions comprise a substance having peroxidative actlvity ~defined hereinbelow). In the case of many analyses, enzymes~ such 2S oxidase materials lik~ glucose 02idase or cholesterol oxidase, can desirably be included within the 25 reagent/spreadin~ zone for the analysis of the analyte that is a ~ubstra~e for such enzyme.
Generally, the interactive composition also includes a dye providing composition. Such compositions include a compound that~ when oxidized, 30 can couple within itself or with its reduced form to provide a dye. Such autocoupling compounds include a variety of hydroxylated compounds, such as o-aminophenols, 4-alkoxyn~phthols, 4-amino-5-pyrazolones, cresols, pyrogallol, guaiacol, orcinol, 35 cstechol, chloroglucinol, p-dihydroxydiphenylgallic acid, pyrocatechoic acid, and salicylic acid.
Compounds of this type are well known and describ2d ~2~lZBO~
in the literature, such as in The Theory of the Photographic Process, Mees and James, 3rd Edition, 1966, especially in Chapter 17.
As another example, the dye can be provided 5 by oxida~ion of a leuco dye compound. Representative leuco dyes include such subs~ances as triaryl-imidazole leuco dyes and other leuco dyes, as described in U. S. Patent 4,089,747 (~ssued May 16, 1978 to Bruschi) and triarylmethane leuco dyes as lo known in the art.
As yet another example, the dye iB formed by dye-providing compositions that include the condensation products of oxidizable compounds with couplers. Representative oxid~zable compounds 15 include benzidine and its homologs, p-phenyldiamine~, p-aminophenols 9 an aminoantipyrine, e.g.
4-aminoant~pyrine) and the like. A wide range of such couplers including a number of au~ocoupling compounds, is descr~bed in the literature 9 such as in 20 Mees and James, supra, and ~n Kosar, Light Sensitive Systems, 1965, pages 215-249.
The dye is generally diffusible so that it can move into the permeable registration zone from the reagent/spreading ~one.
2s In a preferred embodiment of the assay of this invention, the reagent/spreading zone comprises an interactive composition necessary for ~he quantiflable detection of glucose in whole blood.
Basically, this interactive composition comprises 30 glucose oxidase which interacts with the analyte glucose, a peroxidative substance (e.g. peroxidase or others known in the art), ~n aminoantipyrine oxidizable compound (e.g. 4-aminoantipyrine), a suitable buffer which provides a pH in the r~nge of 35 from about 4 to about 7 under conditions of use (i.e~
when spotted with a whole blood sample), and a coupler which will react with the am~noantipyrlne in ~2~6~2 it~ oxidized state. These rea~en~s are well known ln the art, ~s described for example, in U. S. Patent 4,098,574 (issued July 4, 1978 to myself). ~ny of a number of couplers (e.g. phenols, naphthols, sub~tituted anilines, etc.) can be used in the practice of this invention a~ long as they, wlth a suitable oxidlzable compound, can provide a dye detectable at a wavelength greater than about 600 nm, and preferabaly greater than about 630 nm.
Useful couplers for the glucose assay of this invention include toluidine compounds including, for example 9 those described in Japanese Patent Publication 83-2220Q (published May 7, lg83);
European Patent Application 68,356 (published January
The dye is generally diffusible so that it can move into the permeable registration zone from the reagent/spreading ~one.
2s In a preferred embodiment of the assay of this invention, the reagent/spreading zone comprises an interactive composition necessary for ~he quantiflable detection of glucose in whole blood.
Basically, this interactive composition comprises 30 glucose oxidase which interacts with the analyte glucose, a peroxidative substance (e.g. peroxidase or others known in the art), ~n aminoantipyrine oxidizable compound (e.g. 4-aminoantipyrine), a suitable buffer which provides a pH in the r~nge of 35 from about 4 to about 7 under conditions of use (i.e~
when spotted with a whole blood sample), and a coupler which will react with the am~noantipyrlne in ~2~6~2 it~ oxidized state. These rea~en~s are well known ln the art, ~s described for example, in U. S. Patent 4,098,574 (issued July 4, 1978 to myself). ~ny of a number of couplers (e.g. phenols, naphthols, sub~tituted anilines, etc.) can be used in the practice of this invention a~ long as they, wlth a suitable oxidlzable compound, can provide a dye detectable at a wavelength greater than about 600 nm, and preferabaly greater than about 630 nm.
Useful couplers for the glucose assay of this invention include toluidine compounds including, for example 9 those described in Japanese Patent Publication 83-2220Q (published May 7, lg83);
European Patent Application 68,356 (published January
5, 1983); U. K. Patent 2~107,86~ (published October ~2, 1981); and Japanese P~tent Publication 5B-898 (published January 6, 1983~. Examples of such useful toluidine compounds include: N-ethyl-N-2~sulfoethyl-m-toluidine, ~-ethyl-N-2 carboxyethyl-m-toluid~ne, N-2-carboxyethyl-m-toluidine, N-sulfomethyl-~-toluidine, N-methyl-No(2,3-dihydroxypropyl)-m-toluidine, and the llke.
Other useful couplers in~lude substituted aniline compounds such as 8~anilino-1-naphthalene-sulfonic acid and N-methyl~N~sulfopropylaniline, 1,7-dihydroxynaphthalene and others known in the art.
Similarly 9 in another embodiment of this invent~on, a cholesterol assay utilizes a reagent¦spreading zone conta~ning choles~erol oxidase which interacts with th~ analyte cholesterol, cholesterol ester hydrolase, a pero~idatlve ~ubstance ~e.g. peroxidase or others known in the art), an aminoantipyrine oxidizable compound ~e.g.
4-aminoantipyrine), a suitable buffer which providex a pH ln the range of from about 4 to about 7 under conditions of use, and a suitable coupler ~e.g. a toluidine or a sub6tituted anlline or others noted hereinabove~.
lZ~L2~02 The dry analytic~l elements of this invention have only two essential zones, namely reagent/spreading zone con~ainlng the interactive composition described hereinabove and a registration 5 zone for receiving the dye resul~ing from ln~eraction of the interactive composition with the analyte.
These zones can be self-supporting (l.e. having integrity), but preferably they are carried on a suitable support. Such a support ean be any suitable lo dim~nsion~lly stable, and preferably, transparent (i.e. radiation transmissiYe~ material which transmits electromagnetic radi~tion of a wavelength between about 200 and about 900 nm. A support of choice for a particular element should be compatible 15 with the ~ntended mode of detection (reflection, fluorescence, or transmission spectroscopy~. Useul support materials include polystyrene, polyesters (e.g. poly(ethylene t~rephthalate~), polycarbonates, cellulose esters (e.g. cellulose acetate), etc.
20 Preferably, the registration zone is lmmediately ad~acent the support although an optional subbing zone can be interposed, if desired. The zones of the element are in fluid contact with each other, meaning that fluids and reagents and react~on products ln the 1uids can pass between superposed r~gions of ad~acent zones. Stated in another manner, fluid contact refers to the ability to ~ransport componen~s of a fluid between the zones in 1uid contact.
Preferably, the zones are separate coated layPrs, 30 although one or more zones can be in a single layer of an element.
The registration zone of the elements receives react~on products ~ormed or released in the reagent/spreading zone. The components of such zones 35 are well known as descr~bed in, for example, the patents noted hereinbelow with regard to element configurations and materials in general. Generally, ~2126~2 the registratlon zone contains a hydrophilic binder material~ such as gelatln; a hardener, if de~ired;
and a surfactant.
The elements of thi~ invention can also 5 optionally include additional nonessentlal zones having specialized functions, e.g. making element manufacture more convenient. For example, it is common practice ~o use additional zones to promote or control adhesion between other zones. Such zones ~re lo co~monly referred to as "binder" zones or t'subbing' zones and are well known in the art. Such subb1ng zones generally contain one or more naturally-occurring or synthetic polym~ric materials ~ncludin~
gelatin or o~her naturally occurring colloids; or 15 homopolymers and copolymers 9 such as poly~cryl-amide~, poly(vinyl pyrrolidone), poly(n-isopropyl-acrylamide), poly(acrylamide-co N-vinyl-2-pyrrolidone) and similar copolymers.
An advantage o the assay of ~his invention, 20 however, is that the elements used therein do not have a radiation-blocking zone or layer, also known sometimes as a reflective zone or layer. Such zones tend to slow down the diffusion of or retsin ma~y dyes, and hence make the assay slower or less 25 accurate. Some dyes will not diffuse through this zone at all. For example, the dye formed in an element for determining glucose containing an aminoantipyrine and 8-anilino-1-naphthalenesulfonic acid will not diffuse through a radiation-blocking 30 ~one to an appreciable extent. Hence, the assay and element of this invention have distinct advantages by overcoming this problem.
The coverage of eaeh component or reagent in the interactive composit~on described hereinabove can 35 be widely varied depending upon the analyte to be determined. These coverages are well withl~ the skill of the worker in the art. For example, in an ~o~
element designed to assay glucose in whole blood, glueose oxidase is generally present in a coverage of up to about 40,000, and preferably from about 20,000 to about 30,000, U/m2. The peroxidative substance ~e.g. peroxidase) is generally present in a coverage of up to about 40,000, and preferably from about 20,000 ~o about 30,000, U/m2. The aminoantipyrine oxidizable compound is generally present in a cover-age of up to about 2, and preferably from about 0.3 to about 1.5, g/m2. A buffer (e.g. 3,3-dimethyl-glutaric acid) is generally present in a coverage of up to about 20, and preferably from about 1 ~o about 10, g/m2. A coupler to react with the aminoanti-pyrine (e.g. a toluidîne or 8-anilino-1-naphthalene-sulfonic acid) is generally present in a coverage of up to about 5, and preferably from about 0.5 to about 2 g/m 2 .
One or more zones (or layers) of the ele ments of this invention can contain a variety of one or more other desirable, but optional components, including surfactants, thickeners, enzyme activators, coupler solvents, buffers, binders, hardeners, etc.
These components can be present in amounts known to one skilled in the art. Representative element com-ponents are described, for e~ample~ in U. S. Patents 4,258,001; 3,992,158; 4,042,335, 4,144,306, all noted hereinabove; 4,132,528 (issued January 2, 1979 to Eikenberry et al); 4,050,898 (issued September 27, 1977 to ~offe et al3; and 4,275,152 (issued June 23, 1981 to Esders et al).
A variety of different elements, depending on the method of assay, can be prepared in accordance with the present invention. Elements can be con-figured in a variety of forms, including elongated tapes of any desired width, sheets or smaller chips.
2~
The assay of this invention can be manual or automated. In general, the amount of ~nalyte in whole blood is determined by taking the element from a supply roll, chip packet or other source and 5 physically contacting it with a ~ample of the whole blood. Such contact can be accomplish~d in any suitable manner, e.g. dipping or immersing the element into the sample or, preferably, by spotting the reagent/spreading zone of the element by hand or lo machine with a drop of the sample by pipette or other suitable dispensing means.
After sample application, the element iB
exposed to any conditioning, such as incubation, heating or the like, that may be desirable to quicken 15 or otherwise facilitate obtaining any test result.
The analyte, if present, then interacts wlth the interactive composition at a ra~e based on the concentration of &nalyte in the sample and the rate of formation of the dye ~s determined.
20 Alternatively, in an end-point assay, the amount of dye formed in direct proportion to the analyte concentration is determined by passing the element through a zone in which suitable apparatus for detecting the dye is provided. For example, the dye 25 can be detected with suitable spectrophotometric apparatus and procedures known in the ar~.
In the following examples, Zonyl FSN~ was obtained from DuPont (Wilmington, Delaware), peroxidase was purchased from M~les Laboratories 30 (Elkhart, Indiana)9 glucose oxidase waæ obtained from Sigma Corp. (St. Louis, Missouri)9 cholestervl e&ter hydrolase was purchased from Enzyme Development Corp.
(New York, N. Y.) and cholesterol oxidase was purchased from Up~ohn Corp. ~Kalamazoo~ Mich~gan).
35 All other reagents and materials were obtained from Eastman Kodak Company ~Roches~er, New York).
~2~oæ
The following examples are provided to illustrate the practice of the present invention:
Example 1 - Glucose As~ay of th~s Inventlon and Comparison to Prlor Art Assay8 This is a comparative example comparing an assay of this invention for determin~ng glucose to prior art glucose assays.
An analytical element for the quantitative lo determinat~on of glucose in undiluted whole blood was prepared according to ~his inventioll in the following manner. On & poly(ethylene terephthalate) film support were coated, in order, a registration layer and a reagent/spreading layer having the component 15 materials listed below.
-22- ~oæ
N N N N~1 N ~1 N N N C`l C~ N \
El Ei E~ 3 ~3 El \
~ 0 OOP ~ ~ 0 O O C~0 0 O U~ U~ \
O ~I 00 C`~o O \
C~ 0 0 1 ~ O O \
00 0 o ~ ~ O ^O t~ O \
~1 'O O I ~ O \
O 00 O ~
~ \
o ~ a~ ~ O O
C q~ ~00 U~ \
O S~ O
c~ ~ O Q~ \
O ~ ~ JJ ~ ~!
f~ ~ O O a~ ~ ~
~ X ~ ~ ~ \
o Q) ~ o ,~ - o a~ cq ~ \
C~ U~ ~ ~! U ~ ~
a~ o ~ ~ ~ \
e~ ~ o o~ r~ \
SJ ~ O Q3 ~ V r-l V
:1 0 1 ~ a v J~ 3 ~1 2 ~ rl O C) ~ ~ ~3 v,l e :~ o a~ ~ ~
Q C~ ~ P~ 0 U ~r~ ~.,1 rl ~ ~ :1 ~r~ a O
co p, ~~ U ~ O ~ I 0~ 4 ~ 4 1~ ~ u~
J ~ ~ X ~ \
o ~_~ o ~ z ~ O ~ O ~; ~ a cn ~
1 0 0 ~ E 0 ~~ a~ C~ \
t.) ~ ~1 -r~ rl r ~ a .
a ~ ~ ~ X o t) 0 ~ 0 ~I E~ ~ ~ \
¢ ~ ~ q o o o ~ 1 a~ o ~
~ C ~
~0 ~ \
C~C ~ \
~2~2~60;i~
Each of several samples of this analytical el~ment was spotted with 10 ~L samples of undiluted whole blood containing varied amounts of glucose (0 600 mg/dL). Each element sumple Wa6 incubated at 5 room temperature for up to 5 minutes, and reflect~nce density readings were taken at 660 nm at varlous times within the incubation period using a conventional spectrophotometer.
The results of the spectrophotometric lo readings, provided in FIG. 1, illustrate excellent differentiation between glucose concentrations and rapid analysis (~.e. within about 2 to 3 minutes) with the assay of this invention.
The prior art assays evaluated in this 15 example utili~ed the analytical elements described hereinbelow which are labeled Controls A and B.
-24- ~2~
\\\
\ \
~o ~o oo~o ooao ~ ~ ~ ~ \
,, U~ U~ o ~ o ~oo \~
o o e~l ,~ C`~ o o,~
o U~ U~ U~ ~ ~ U) ~ ~o o ~ O L O O O O /r C~
O 0 O . . ~ O 00 1 1 \ ~
¢ C~ 00 0;~ 000 ~
L~ U~ \
~I ~ U~ O ~ O
O O ~ ~ J ~1~ e~ O ~ ~ C~ ~10 0 ~J l ll l l l I I I I I O O I OC:\ \ ~
J_~ ~U~~U~ ~J-I U5LO ~I U~ ~0~ ~ \
s:: o O o c:, o o ô o a~
O OO OO ~ ~ \
~o I ~0 ~\
al , , ~ o o ô ,5: \
P. ~ ~ ~1 0 C~l ~ P~
o ~ ~ ~ a Q) C ~ ~
O
C~ ~ t) ~ U J ~ O I
~ o~ ~~ ~ SJ$ ~ ~ ~
. ~, X ~ ~ ~ ~ ~
ca O ~1~ ~o ~ t ~ ~ ~ P~\
E 1 ~ ~O ~I) E ~ rl ~ a) X ~ \
~a ooz ~ Z; 'I ,~ to o a cn ~ ~_ U Ql tll ~ rl a) q~ N
rl E~ l F. J~ ~1 J~ I a ~ ~ ~ ~ x ~ x o o td J~ :~~ ~ 0~J ?~ l u ~ ~ o u P~
s~ ~ ~ g ~ g ~ \ \\
v a~ z u~ \~
\
\ \
oo o ~o Id C ), ~1 t~O~ \ \
~Uo ~ ~ ~ \~\~
S~
cn ~2~ 2 Controls A and B are similar to the elements described in Example 4 of U. S. Patent 47258,001 and in Example 2 of Japanese Patent Publication 57~1982)-101760, both noted here~nabove.
Each of several samples of these elements was spotted with 10 ~L samples of undiluted whole blood cont~inlng varied amountæ of glucose ~60-650 mg/dL3. Each element sample w~s incubated at room tempPrature for up to 5 minutes, and reflectance lo density readings were taken at 565 nm at various times within the incubation period using a conventional spectrophotometer.
The results of the spectrophotometric readings are provided in FIGS, 2 and 3 for Control 15 elements A and B, respect~vely. The results in FIGS.
2 and 3 indicate that the assay with Controls A and B
are considerably slower than the assay of this invention, particularly at the higher glucose concentrations. I~e response curves show that an end 20 point has not been reached even after 5 minutes. The results also indicate ~hat, at the higher glucose concentrations, there ls very poor discrimination between concentration levels.
Example 2 - Glucose Assay of this Invention Using Toluidine Coupler and Comparison with Prior Art AssaY
_ ~
This is a comparat~ve example similar to Example 1 except ~hat a toluidine coupler wAs used in place of 8-anilino-1-naphthalenesulfonic acid.
An element was prepared according to thi~
invention like that described in Example 1 except that from 0.5 to 5 g/m2 of ~-ethyl-N-2-suloethyl-m-toluidine was used as the coupler compound in place of 8-anilino-1-naphthalenesulfonic acîd.
A Control element C was prepared 8 imilarly except that it included a radiation block~ng/filter layer interpoæed between the reagentlspreading and ~12~
registra~ion layers. This additional layer was constructed like that for Controls A and B of Example 1. Control C is representative of the teachlng of U. S. Patent 4,042,335 (noted hereinabove)~
Each of several samples of each element was spotted with 10 ~L ~amples of undiluted whole blood containing varied amounts of glucose ~0 590 mg/dL) glucose and evaluated as the element sample& were evaluated in Example 1. The element of this lo invention was evaluated at 660 nm to avoid hemoglobin interference, while Control C was evaluated at 565 nm since the radiation blocking/filter layer blocked out the hemoglobin interference. The dye released using the toluidine coupler can be ~pectrophotometrically 15 detected at either wavelength although the ~max is ~loser to 565 nm. The results of the spectrophotometric readings are provided in FIGS. 4 and 5 for the invention element and Control G
element, respectively.
These results indicate that the as~ay of this invention provides a more rapid assay than the Control C assay. The response curves for Control C
are still rising after 5 mlnu~es, particularly at the higher glucose concentrations whereas the invention 25 response curves flatten out very quiekly ~less than 3 minutes). Also, there is poor discrimination with the Control C element especially at the higher glucose concentration levels.
Example 3 - Choles~erol Assay An analytical element for the quantitative determination of cholesterol in whole blood was prepared in the following manner. On a poly~ethylene terephthalate) film support were coa~ed, in order, a registration layer and a reagent/spreading layer - 35 having the component materials listed below.
- -27- :I29l 2~i~æ
\
\ \
_ `~
p o~ o \
U~ o~o~U'~ ~ oOoo ~o ~oC~J \\
, U~OO _1~oO o ,1 1 U~
l ~ ~ U~ oL"
o o U~ ~ o C~ , . o \ `.
o o oo . ~ I I oo ~ ooO \~
C~ ~ o t~ \
O ~ ~ D ~ 0 5 ~ 0 ~ e~
rl O ~ O ~ S~ 9 Q~ J-O to~. O. ~ ~ o a) ~ ~, E~ ~o C ~ ol ~ ~:
a) I,~ IRl O I ~ 1 ~ ,S
1 0 00 ~ 0 ~~ ~ ~ ~ ~rQ ~ ~ ~
X .~ ~ ~ ~ ~ \
o I q) ~ ~ o W ~ U a~ o~ ~3~ ~1 ~ S~
h ,~ :~ J~ o C ~ - ~ ~ ~ ~ CO ~ ~rC ~ ~ ~ ~ ~ ~ ~ 03 X ~ o~o ~ _ u ~ O ~ ~a o .a~ ~ o ~ ~ u~
_~ CO .. ~ ~1 ~ .1: '~ I ~ ~ I ~ ~ O ~1 ~ , ~o ~ ~~o J~ U ~ I Q~ O O tO
~ o ~ æ ~ ~ ~ ~ ~ ~
; ~XO I r~ 1] I d O a) ~ ~ PC
I O c~O ~-~1 0 ~I ~ ~ ~ ~ rl _~
~q o ~o î o a~ ~o ~~ o~ ,l ~ ~ o ~ a~ ~, O o ~1 ~q ~ ~ ~ P~
0 0 0 ~ ~ ~ O I ~ ~ ~! a~ ~ o ~ u~ Zp~ ~ \~
'~ ~ a~ h \~
a~ ~ \~
~2~Z~6~2 Each of several samples of this analytical element was spotted with a 10 ~L sample of undiluted whole blood containing varied amounts of chole6terol (166, 226, 287 and 369 mg/L). Each 5 element sample was incubated at 37C for up to 5 minutes, and reflectance density readings were taken at 630 nm at the end of the incubation period for each cholesterol concentration. The observed density readings were plotted as a function of concentration lo to give the calibration curve shown in FIG. 6.
The invention has been described in detail with particulsr reference to preferred embod~ments thereof, but it will be understood ~hat variat~ons and modificatioas can be effected w~thin the spirlt 15 and scope of the invention.
Other useful couplers in~lude substituted aniline compounds such as 8~anilino-1-naphthalene-sulfonic acid and N-methyl~N~sulfopropylaniline, 1,7-dihydroxynaphthalene and others known in the art.
Similarly 9 in another embodiment of this invent~on, a cholesterol assay utilizes a reagent¦spreading zone conta~ning choles~erol oxidase which interacts with th~ analyte cholesterol, cholesterol ester hydrolase, a pero~idatlve ~ubstance ~e.g. peroxidase or others known in the art), an aminoantipyrine oxidizable compound ~e.g.
4-aminoantipyrine), a suitable buffer which providex a pH ln the range of from about 4 to about 7 under conditions of use, and a suitable coupler ~e.g. a toluidine or a sub6tituted anlline or others noted hereinabove~.
lZ~L2~02 The dry analytic~l elements of this invention have only two essential zones, namely reagent/spreading zone con~ainlng the interactive composition described hereinabove and a registration 5 zone for receiving the dye resul~ing from ln~eraction of the interactive composition with the analyte.
These zones can be self-supporting (l.e. having integrity), but preferably they are carried on a suitable support. Such a support ean be any suitable lo dim~nsion~lly stable, and preferably, transparent (i.e. radiation transmissiYe~ material which transmits electromagnetic radi~tion of a wavelength between about 200 and about 900 nm. A support of choice for a particular element should be compatible 15 with the ~ntended mode of detection (reflection, fluorescence, or transmission spectroscopy~. Useul support materials include polystyrene, polyesters (e.g. poly(ethylene t~rephthalate~), polycarbonates, cellulose esters (e.g. cellulose acetate), etc.
20 Preferably, the registration zone is lmmediately ad~acent the support although an optional subbing zone can be interposed, if desired. The zones of the element are in fluid contact with each other, meaning that fluids and reagents and react~on products ln the 1uids can pass between superposed r~gions of ad~acent zones. Stated in another manner, fluid contact refers to the ability to ~ransport componen~s of a fluid between the zones in 1uid contact.
Preferably, the zones are separate coated layPrs, 30 although one or more zones can be in a single layer of an element.
The registration zone of the elements receives react~on products ~ormed or released in the reagent/spreading zone. The components of such zones 35 are well known as descr~bed in, for example, the patents noted hereinbelow with regard to element configurations and materials in general. Generally, ~2126~2 the registratlon zone contains a hydrophilic binder material~ such as gelatln; a hardener, if de~ired;
and a surfactant.
The elements of thi~ invention can also 5 optionally include additional nonessentlal zones having specialized functions, e.g. making element manufacture more convenient. For example, it is common practice ~o use additional zones to promote or control adhesion between other zones. Such zones ~re lo co~monly referred to as "binder" zones or t'subbing' zones and are well known in the art. Such subb1ng zones generally contain one or more naturally-occurring or synthetic polym~ric materials ~ncludin~
gelatin or o~her naturally occurring colloids; or 15 homopolymers and copolymers 9 such as poly~cryl-amide~, poly(vinyl pyrrolidone), poly(n-isopropyl-acrylamide), poly(acrylamide-co N-vinyl-2-pyrrolidone) and similar copolymers.
An advantage o the assay of ~his invention, 20 however, is that the elements used therein do not have a radiation-blocking zone or layer, also known sometimes as a reflective zone or layer. Such zones tend to slow down the diffusion of or retsin ma~y dyes, and hence make the assay slower or less 25 accurate. Some dyes will not diffuse through this zone at all. For example, the dye formed in an element for determining glucose containing an aminoantipyrine and 8-anilino-1-naphthalenesulfonic acid will not diffuse through a radiation-blocking 30 ~one to an appreciable extent. Hence, the assay and element of this invention have distinct advantages by overcoming this problem.
The coverage of eaeh component or reagent in the interactive composit~on described hereinabove can 35 be widely varied depending upon the analyte to be determined. These coverages are well withl~ the skill of the worker in the art. For example, in an ~o~
element designed to assay glucose in whole blood, glueose oxidase is generally present in a coverage of up to about 40,000, and preferably from about 20,000 to about 30,000, U/m2. The peroxidative substance ~e.g. peroxidase) is generally present in a coverage of up to about 40,000, and preferably from about 20,000 ~o about 30,000, U/m2. The aminoantipyrine oxidizable compound is generally present in a cover-age of up to about 2, and preferably from about 0.3 to about 1.5, g/m2. A buffer (e.g. 3,3-dimethyl-glutaric acid) is generally present in a coverage of up to about 20, and preferably from about 1 ~o about 10, g/m2. A coupler to react with the aminoanti-pyrine (e.g. a toluidîne or 8-anilino-1-naphthalene-sulfonic acid) is generally present in a coverage of up to about 5, and preferably from about 0.5 to about 2 g/m 2 .
One or more zones (or layers) of the ele ments of this invention can contain a variety of one or more other desirable, but optional components, including surfactants, thickeners, enzyme activators, coupler solvents, buffers, binders, hardeners, etc.
These components can be present in amounts known to one skilled in the art. Representative element com-ponents are described, for e~ample~ in U. S. Patents 4,258,001; 3,992,158; 4,042,335, 4,144,306, all noted hereinabove; 4,132,528 (issued January 2, 1979 to Eikenberry et al); 4,050,898 (issued September 27, 1977 to ~offe et al3; and 4,275,152 (issued June 23, 1981 to Esders et al).
A variety of different elements, depending on the method of assay, can be prepared in accordance with the present invention. Elements can be con-figured in a variety of forms, including elongated tapes of any desired width, sheets or smaller chips.
2~
The assay of this invention can be manual or automated. In general, the amount of ~nalyte in whole blood is determined by taking the element from a supply roll, chip packet or other source and 5 physically contacting it with a ~ample of the whole blood. Such contact can be accomplish~d in any suitable manner, e.g. dipping or immersing the element into the sample or, preferably, by spotting the reagent/spreading zone of the element by hand or lo machine with a drop of the sample by pipette or other suitable dispensing means.
After sample application, the element iB
exposed to any conditioning, such as incubation, heating or the like, that may be desirable to quicken 15 or otherwise facilitate obtaining any test result.
The analyte, if present, then interacts wlth the interactive composition at a ra~e based on the concentration of &nalyte in the sample and the rate of formation of the dye ~s determined.
20 Alternatively, in an end-point assay, the amount of dye formed in direct proportion to the analyte concentration is determined by passing the element through a zone in which suitable apparatus for detecting the dye is provided. For example, the dye 25 can be detected with suitable spectrophotometric apparatus and procedures known in the ar~.
In the following examples, Zonyl FSN~ was obtained from DuPont (Wilmington, Delaware), peroxidase was purchased from M~les Laboratories 30 (Elkhart, Indiana)9 glucose oxidase waæ obtained from Sigma Corp. (St. Louis, Missouri)9 cholestervl e&ter hydrolase was purchased from Enzyme Development Corp.
(New York, N. Y.) and cholesterol oxidase was purchased from Up~ohn Corp. ~Kalamazoo~ Mich~gan).
35 All other reagents and materials were obtained from Eastman Kodak Company ~Roches~er, New York).
~2~oæ
The following examples are provided to illustrate the practice of the present invention:
Example 1 - Glucose As~ay of th~s Inventlon and Comparison to Prlor Art Assay8 This is a comparative example comparing an assay of this invention for determin~ng glucose to prior art glucose assays.
An analytical element for the quantitative lo determinat~on of glucose in undiluted whole blood was prepared according to ~his inventioll in the following manner. On & poly(ethylene terephthalate) film support were coated, in order, a registration layer and a reagent/spreading layer having the component 15 materials listed below.
-22- ~oæ
N N N N~1 N ~1 N N N C`l C~ N \
El Ei E~ 3 ~3 El \
~ 0 OOP ~ ~ 0 O O C~0 0 O U~ U~ \
O ~I 00 C`~o O \
C~ 0 0 1 ~ O O \
00 0 o ~ ~ O ^O t~ O \
~1 'O O I ~ O \
O 00 O ~
~ \
o ~ a~ ~ O O
C q~ ~00 U~ \
O S~ O
c~ ~ O Q~ \
O ~ ~ JJ ~ ~!
f~ ~ O O a~ ~ ~
~ X ~ ~ ~ \
o Q) ~ o ,~ - o a~ cq ~ \
C~ U~ ~ ~! U ~ ~
a~ o ~ ~ ~ \
e~ ~ o o~ r~ \
SJ ~ O Q3 ~ V r-l V
:1 0 1 ~ a v J~ 3 ~1 2 ~ rl O C) ~ ~ ~3 v,l e :~ o a~ ~ ~
Q C~ ~ P~ 0 U ~r~ ~.,1 rl ~ ~ :1 ~r~ a O
co p, ~~ U ~ O ~ I 0~ 4 ~ 4 1~ ~ u~
J ~ ~ X ~ \
o ~_~ o ~ z ~ O ~ O ~; ~ a cn ~
1 0 0 ~ E 0 ~~ a~ C~ \
t.) ~ ~1 -r~ rl r ~ a .
a ~ ~ ~ X o t) 0 ~ 0 ~I E~ ~ ~ \
¢ ~ ~ q o o o ~ 1 a~ o ~
~ C ~
~0 ~ \
C~C ~ \
~2~2~60;i~
Each of several samples of this analytical el~ment was spotted with 10 ~L samples of undiluted whole blood containing varied amounts of glucose (0 600 mg/dL). Each element sumple Wa6 incubated at 5 room temperature for up to 5 minutes, and reflect~nce density readings were taken at 660 nm at varlous times within the incubation period using a conventional spectrophotometer.
The results of the spectrophotometric lo readings, provided in FIG. 1, illustrate excellent differentiation between glucose concentrations and rapid analysis (~.e. within about 2 to 3 minutes) with the assay of this invention.
The prior art assays evaluated in this 15 example utili~ed the analytical elements described hereinbelow which are labeled Controls A and B.
-24- ~2~
\\\
\ \
~o ~o oo~o ooao ~ ~ ~ ~ \
,, U~ U~ o ~ o ~oo \~
o o e~l ,~ C`~ o o,~
o U~ U~ U~ ~ ~ U) ~ ~o o ~ O L O O O O /r C~
O 0 O . . ~ O 00 1 1 \ ~
¢ C~ 00 0;~ 000 ~
L~ U~ \
~I ~ U~ O ~ O
O O ~ ~ J ~1~ e~ O ~ ~ C~ ~10 0 ~J l ll l l l I I I I I O O I OC:\ \ ~
J_~ ~U~~U~ ~J-I U5LO ~I U~ ~0~ ~ \
s:: o O o c:, o o ô o a~
O OO OO ~ ~ \
~o I ~0 ~\
al , , ~ o o ô ,5: \
P. ~ ~ ~1 0 C~l ~ P~
o ~ ~ ~ a Q) C ~ ~
O
C~ ~ t) ~ U J ~ O I
~ o~ ~~ ~ SJ$ ~ ~ ~
. ~, X ~ ~ ~ ~ ~
ca O ~1~ ~o ~ t ~ ~ ~ P~\
E 1 ~ ~O ~I) E ~ rl ~ a) X ~ \
~a ooz ~ Z; 'I ,~ to o a cn ~ ~_ U Ql tll ~ rl a) q~ N
rl E~ l F. J~ ~1 J~ I a ~ ~ ~ ~ x ~ x o o td J~ :~~ ~ 0~J ?~ l u ~ ~ o u P~
s~ ~ ~ g ~ g ~ \ \\
v a~ z u~ \~
\
\ \
oo o ~o Id C ), ~1 t~O~ \ \
~Uo ~ ~ ~ \~\~
S~
cn ~2~ 2 Controls A and B are similar to the elements described in Example 4 of U. S. Patent 47258,001 and in Example 2 of Japanese Patent Publication 57~1982)-101760, both noted here~nabove.
Each of several samples of these elements was spotted with 10 ~L samples of undiluted whole blood cont~inlng varied amountæ of glucose ~60-650 mg/dL3. Each element sample w~s incubated at room tempPrature for up to 5 minutes, and reflectance lo density readings were taken at 565 nm at various times within the incubation period using a conventional spectrophotometer.
The results of the spectrophotometric readings are provided in FIGS, 2 and 3 for Control 15 elements A and B, respect~vely. The results in FIGS.
2 and 3 indicate that the assay with Controls A and B
are considerably slower than the assay of this invention, particularly at the higher glucose concentrations. I~e response curves show that an end 20 point has not been reached even after 5 minutes. The results also indicate ~hat, at the higher glucose concentrations, there ls very poor discrimination between concentration levels.
Example 2 - Glucose Assay of this Invention Using Toluidine Coupler and Comparison with Prior Art AssaY
_ ~
This is a comparat~ve example similar to Example 1 except ~hat a toluidine coupler wAs used in place of 8-anilino-1-naphthalenesulfonic acid.
An element was prepared according to thi~
invention like that described in Example 1 except that from 0.5 to 5 g/m2 of ~-ethyl-N-2-suloethyl-m-toluidine was used as the coupler compound in place of 8-anilino-1-naphthalenesulfonic acîd.
A Control element C was prepared 8 imilarly except that it included a radiation block~ng/filter layer interpoæed between the reagentlspreading and ~12~
registra~ion layers. This additional layer was constructed like that for Controls A and B of Example 1. Control C is representative of the teachlng of U. S. Patent 4,042,335 (noted hereinabove)~
Each of several samples of each element was spotted with 10 ~L ~amples of undiluted whole blood containing varied amounts of glucose ~0 590 mg/dL) glucose and evaluated as the element sample& were evaluated in Example 1. The element of this lo invention was evaluated at 660 nm to avoid hemoglobin interference, while Control C was evaluated at 565 nm since the radiation blocking/filter layer blocked out the hemoglobin interference. The dye released using the toluidine coupler can be ~pectrophotometrically 15 detected at either wavelength although the ~max is ~loser to 565 nm. The results of the spectrophotometric readings are provided in FIGS. 4 and 5 for the invention element and Control G
element, respectively.
These results indicate that the as~ay of this invention provides a more rapid assay than the Control C assay. The response curves for Control C
are still rising after 5 mlnu~es, particularly at the higher glucose concentrations whereas the invention 25 response curves flatten out very quiekly ~less than 3 minutes). Also, there is poor discrimination with the Control C element especially at the higher glucose concentration levels.
Example 3 - Choles~erol Assay An analytical element for the quantitative determination of cholesterol in whole blood was prepared in the following manner. On a poly~ethylene terephthalate) film support were coa~ed, in order, a registration layer and a reagent/spreading layer - 35 having the component materials listed below.
- -27- :I29l 2~i~æ
\
\ \
_ `~
p o~ o \
U~ o~o~U'~ ~ oOoo ~o ~oC~J \\
, U~OO _1~oO o ,1 1 U~
l ~ ~ U~ oL"
o o U~ ~ o C~ , . o \ `.
o o oo . ~ I I oo ~ ooO \~
C~ ~ o t~ \
O ~ ~ D ~ 0 5 ~ 0 ~ e~
rl O ~ O ~ S~ 9 Q~ J-O to~. O. ~ ~ o a) ~ ~, E~ ~o C ~ ol ~ ~:
a) I,~ IRl O I ~ 1 ~ ,S
1 0 00 ~ 0 ~~ ~ ~ ~ ~rQ ~ ~ ~
X .~ ~ ~ ~ ~ \
o I q) ~ ~ o W ~ U a~ o~ ~3~ ~1 ~ S~
h ,~ :~ J~ o C ~ - ~ ~ ~ ~ CO ~ ~rC ~ ~ ~ ~ ~ ~ ~ 03 X ~ o~o ~ _ u ~ O ~ ~a o .a~ ~ o ~ ~ u~
_~ CO .. ~ ~1 ~ .1: '~ I ~ ~ I ~ ~ O ~1 ~ , ~o ~ ~~o J~ U ~ I Q~ O O tO
~ o ~ æ ~ ~ ~ ~ ~ ~
; ~XO I r~ 1] I d O a) ~ ~ PC
I O c~O ~-~1 0 ~I ~ ~ ~ ~ rl _~
~q o ~o î o a~ ~o ~~ o~ ,l ~ ~ o ~ a~ ~, O o ~1 ~q ~ ~ ~ P~
0 0 0 ~ ~ ~ O I ~ ~ ~! a~ ~ o ~ u~ Zp~ ~ \~
'~ ~ a~ h \~
a~ ~ \~
~2~Z~6~2 Each of several samples of this analytical element was spotted with a 10 ~L sample of undiluted whole blood containing varied amounts of chole6terol (166, 226, 287 and 369 mg/L). Each 5 element sample was incubated at 37C for up to 5 minutes, and reflectance density readings were taken at 630 nm at the end of the incubation period for each cholesterol concentration. The observed density readings were plotted as a function of concentration lo to give the calibration curve shown in FIG. 6.
The invention has been described in detail with particulsr reference to preferred embod~ments thereof, but it will be understood ~hat variat~ons and modificatioas can be effected w~thin the spirlt 15 and scope of the invention.
Claims (30)
1. A method for the determination of an analyte in whole blood, said method comprising the steps of:
(A) physically contacting a sample of whole blood and a multizone element, said element consisting essentially of a support having thereon, in order and in fluid contact, a registration zone and a reagent/spreading zone, said reagent/spreading zone having a void volume and average pore size effective to accommodate whole blood, and containing an interactive composition capable of providing, upon interaction with said analyte, a dye which can be spectrophotometrically detected at a wavelength greater than about 600 nm; and (B) detecting said dye at a wavelength greater than about 600 nm.
(A) physically contacting a sample of whole blood and a multizone element, said element consisting essentially of a support having thereon, in order and in fluid contact, a registration zone and a reagent/spreading zone, said reagent/spreading zone having a void volume and average pore size effective to accommodate whole blood, and containing an interactive composition capable of providing, upon interaction with said analyte, a dye which can be spectrophotometrically detected at a wavelength greater than about 600 nm; and (B) detecting said dye at a wavelength greater than about 600 nm.
2. The method of claim 1 wherein said reagent/spreading zone comprises a particulate structure comprising a plurality of particles non-swellable in and impermeable to whole blood, said particles having a particle size of from about 1 to about 200 microns and being bonded on surface areas of adjacent particles where said adjacent particles are in closest proximity to form a coherent, three-dimensional lattice which is non-swellable in whole blood.
3. The method of claim 2 wherein said particles are chemically bonded through reactive groups which are incorporated in said particles.
4. The method of claim 2 wherein said particles are bonded with an adhesive material.
5. The method of claim 1 wherein said reagent/spreading zone comprises a fibrous material.
6. The method of claim 1 wherein said interactive composition comprises a substance having peroxidative activity.
7. The method of claim 1 wherein said void volume is from about 40 to about 60 percent and said average pore size is at least 5 microns.
8. A method for the determination of an analyte in whole blood, said method comprising the steps of:
(A) physically contacting a sample of whole blood and a multizone element, said element consisting of a support having thereon, in order and in fluid contact, a registration zone, a subbing zone and a reagent/spreading zone, said reagent/spreading zone having a void volume and average pore size effective to accommodate whole blood, and containing an interactive composition capable of providing, upon interaction with said analyte, a dye which can be spectrophotometrically detected at a wavelength greater than about 600 nm; and (B) quantitatively detecting said dye at a wavelength greater than about 600 nm.
(A) physically contacting a sample of whole blood and a multizone element, said element consisting of a support having thereon, in order and in fluid contact, a registration zone, a subbing zone and a reagent/spreading zone, said reagent/spreading zone having a void volume and average pore size effective to accommodate whole blood, and containing an interactive composition capable of providing, upon interaction with said analyte, a dye which can be spectrophotometrically detected at a wavelength greater than about 600 nm; and (B) quantitatively detecting said dye at a wavelength greater than about 600 nm.
9. A method for the determination of an analyte in whole blood, said method comprising the steps of:
(A) physically contacting a sample of whole blood and a multizone element, said element consisting essentially of a support having thereon, in order and in fluid contact, a registration zone and a reagent/spreading zone, said reagent/spreading zone containing an interactive composition capable of providing, upon interaction with said analyte, a dye which can be spectrophotometrically detected at a wavelength greater than about 600 nm, said reagent/spreading zone also comprising a particulate structure having a void volume of from about 40 to about 60 percent and an average pore size of at least 5 microns, said particulate structure comprising:
(i) a plurality of heat-stable, organo-polymeric particles non-swellable in and impermeable to whole blood, said particles having particle size of from about 1 to about 200 microns, and (ii) an adhesive, in an amount less than about 10 percent by weight of said particles, comprising an organic polymer different from that of said particles and insoluble in whole blood;
substantially all of said adhesive being concentrated on surface areas of adjacent particles where said adjacent particles are in closest proximity, and bonding said particles into a coherent, three-dimensional lattice which is non-swellable in whole blood; and (B) quantitatively detecting said dye at a wavelength greater than about 600 nm.
(A) physically contacting a sample of whole blood and a multizone element, said element consisting essentially of a support having thereon, in order and in fluid contact, a registration zone and a reagent/spreading zone, said reagent/spreading zone containing an interactive composition capable of providing, upon interaction with said analyte, a dye which can be spectrophotometrically detected at a wavelength greater than about 600 nm, said reagent/spreading zone also comprising a particulate structure having a void volume of from about 40 to about 60 percent and an average pore size of at least 5 microns, said particulate structure comprising:
(i) a plurality of heat-stable, organo-polymeric particles non-swellable in and impermeable to whole blood, said particles having particle size of from about 1 to about 200 microns, and (ii) an adhesive, in an amount less than about 10 percent by weight of said particles, comprising an organic polymer different from that of said particles and insoluble in whole blood;
substantially all of said adhesive being concentrated on surface areas of adjacent particles where said adjacent particles are in closest proximity, and bonding said particles into a coherent, three-dimensional lattice which is non-swellable in whole blood; and (B) quantitatively detecting said dye at a wavelength greater than about 600 nm.
10. The method of claim 9 wherein said analyte is glucose.
11. The method of claim 9 wherein said analyte is cholesterol.
12. A method for the determination of glucose in whole blood, said method comprising the steps of:
(A) physically contacting a sample of whole blood and a multilayer element, said element consisting essentially of a support having thereon, in order and in fluid contact, a registration layer and a reagent/spreading layer, said reagent/spreading layer having a void volume and average pore size effective to accommodate whole blood, and containing a composition comprising glucose oxidase, a substance having peroxidative activity, an aminoantipyrine and ~ color-forming coupler which, upon the interaction of said composition with glucose, provides a dye which can be spectrophotometrically detected at a wavelength greater than about 600 nm; and (B) quantitatively detecting said dye at a wavelength greater than about 600 nm.
(A) physically contacting a sample of whole blood and a multilayer element, said element consisting essentially of a support having thereon, in order and in fluid contact, a registration layer and a reagent/spreading layer, said reagent/spreading layer having a void volume and average pore size effective to accommodate whole blood, and containing a composition comprising glucose oxidase, a substance having peroxidative activity, an aminoantipyrine and ~ color-forming coupler which, upon the interaction of said composition with glucose, provides a dye which can be spectrophotometrically detected at a wavelength greater than about 600 nm; and (B) quantitatively detecting said dye at a wavelength greater than about 600 nm.
13. The method of claim 12 wherein said peroxidative substance is peroxides, and said aminoantipyrine is 4-aminoantipyrine.
14. The method of claim 12 wherein said element comprises a buffer which provides a pH of from about 4 to about 7 under conditions of use.
15. The method of claim 12 wherein said color-forming coupler is a toluidine compound or a substituted aniline compound.
16. A multizone element for the determination of an analyte in whole blood, said element consisting essentially of a support having thereon, in order and in fluid contact, a registration zone and a reagent/spreading zone, said reagent/spreading zone having a void volume and average pore size effective to accommodate whole blood and containing an interactive composition necessary for said determination, said interactive composition comprising a substance having peroxidative activity, and capable of providing, upon interaction with said analyte, a dye which can be spectrophotometrically detected at a wavelength greater than about 600 nm.
17. The element of claim 16 wherein said void volume of said reagent/spreading layer is from about 25 to about 80 percent and said average pore size is at least 5 microns.
18. The element of claim 16 wherein said analyte is glucose.
19. The element of claim 16 wherein said analyte is cholesterol.
20. The element of claim 16 wherein said reagent/spreading zone comprises a fibrous material.
21. A multizone element for the determination of an analyte in whole blood, said element consisting essentially of a support having thereon, in order and in fluid contact, a registration zone and a reagent/spreading zone, said reagent/spreading zone containing an interactive composition necessary for said determination, said interactive composition comprising a substance having peroxidative activity, and capable of providing, upon interaction with said analyte, a dye which can be spectrophotometrically detected at a wavelength greater than about 600 nm, said reagent/spreading zone also comprising a particulate structure having a void volume and average pore size effective to accommodate whole blood, said particulate structure comprising a plurality of particles non-swellable in and impermeable to whole blood, said particles having particle size of from about 1 to about 200 microns and being bonded on surface areas of adjacent particles where said adjacent particles are in closest proximity to form a coherent, three-dimensional lattice which is non-swellable in whole blood.
22. The element of claim 21 wherein said particles are chemically bonded through reactive groups which are a part of said particles.
23. The element of claim 21 wherein said particles are bonded with an adhesive material.
24. A multizone element for the determination of an analyte in whole blood, said element consisting essentially of a support having thereon, in order and in fluid contact, a registration zone and a reagent/spreading zone containing an interactive composition necessary for said determination, said interactive composition comprising a substance having peroxidative activity, and capable of providing, upon interaction with said analyte, a dye which can be spectrophotometrically detected at a wavelength greater than about 600 nm, said reagent/spreading zone also comprising a particulate structure having a void volume of from about 40 to about 60 percent and an average pore size of at least from about 15 to about 65 microns, said particulate structure comprising:
(i) a plurality of heat-stable, organo-polymeric particles non-swellable in and impermeable to whole blood, said particles having a particle size of from about l to about 200 microns, and (ii) an adhesive, in an amount less than about 10 percent by weight of said particles, comprising an organic polymer different from that of said particles and insoluble in whole blood;
substantially all of said adhesive being concentrated on surface areas of adjacent particles where said adjacent particles are in closest proximity, and bonding said particles into a coherent, three-dimensional lattice which is non-swellable in whole blood.
(i) a plurality of heat-stable, organo-polymeric particles non-swellable in and impermeable to whole blood, said particles having a particle size of from about l to about 200 microns, and (ii) an adhesive, in an amount less than about 10 percent by weight of said particles, comprising an organic polymer different from that of said particles and insoluble in whole blood;
substantially all of said adhesive being concentrated on surface areas of adjacent particles where said adjacent particles are in closest proximity, and bonding said particles into a coherent, three-dimensional lattice which is non-swellable in whole blood.
25. The element of claim 24 wherein said particles comprise an addition polymer formed from one or more of the following ethylenically unsaturated polymerizable monomers:
(a) up to 100 weight percent of an amino-substituent-free vinyl carbocyclic aromatic;
(b) up to about 25 weight percent of an acrylic acid ester;
(c) up to 100 weight percent of a methacrylic acid ester;
(d) up to about 30 weight percent of an ethylenically unsaturated carboxylic acid;
(e) up to about 75 weight percent of an ethylenically unsaturated nitrile;
(f) up to about 20 weight percent of an amino-substituted vinyl carbocyclic aromatic;
(g) up to about 20 weight percent of an ethylenically unsaturated crosslinkable monomer;
(h) up to about 20 weight percent of a tertiary aminoalkyl acrylate or methacrylate;
(i) up to 100 weight percent of a N-heterocyclic vinyl monomer; and (j) up to about 20 weight percent of an acrylamide or methacrylamide, and said adhesive comprises an addition polymer formed from a blend of ethylenically unsaturated polymerizable monomers selected from the following group:
A. a blend containing from about 1 to about 35 weight percent of one or more amino-substiuent-free vinyl carbocyclic aromatics and from about 65 to about 99 weight percent of one or more alkyl acrylates or methacrylates;
B. a blend containing from about 20 to about 95 weight percent of one or more amino-substituent-free vinyl carbocyclic aromatics, acrylic or methacrylic acid esters and ethylenically unsaturated polymerizable crosslinkable monomers, and from about 5 to about 80 weight percent of one or more ethylenically unsaturated polymerizable monomers having an active hydrogen or salts thereof; and C. a blend containing from about 15 to 100 weight percent of one or more ethylenically unsaturated monomers selected from the group consisting of 1-vinylimidazole, vinylbenzyl alcohol, ethyl acrylate or an acrylamide or methacrylamide, and up to 85 weight percent of one or more ethylenically unsaturated polymerizable crosslinkable monomers.
(a) up to 100 weight percent of an amino-substituent-free vinyl carbocyclic aromatic;
(b) up to about 25 weight percent of an acrylic acid ester;
(c) up to 100 weight percent of a methacrylic acid ester;
(d) up to about 30 weight percent of an ethylenically unsaturated carboxylic acid;
(e) up to about 75 weight percent of an ethylenically unsaturated nitrile;
(f) up to about 20 weight percent of an amino-substituted vinyl carbocyclic aromatic;
(g) up to about 20 weight percent of an ethylenically unsaturated crosslinkable monomer;
(h) up to about 20 weight percent of a tertiary aminoalkyl acrylate or methacrylate;
(i) up to 100 weight percent of a N-heterocyclic vinyl monomer; and (j) up to about 20 weight percent of an acrylamide or methacrylamide, and said adhesive comprises an addition polymer formed from a blend of ethylenically unsaturated polymerizable monomers selected from the following group:
A. a blend containing from about 1 to about 35 weight percent of one or more amino-substiuent-free vinyl carbocyclic aromatics and from about 65 to about 99 weight percent of one or more alkyl acrylates or methacrylates;
B. a blend containing from about 20 to about 95 weight percent of one or more amino-substituent-free vinyl carbocyclic aromatics, acrylic or methacrylic acid esters and ethylenically unsaturated polymerizable crosslinkable monomers, and from about 5 to about 80 weight percent of one or more ethylenically unsaturated polymerizable monomers having an active hydrogen or salts thereof; and C. a blend containing from about 15 to 100 weight percent of one or more ethylenically unsaturated monomers selected from the group consisting of 1-vinylimidazole, vinylbenzyl alcohol, ethyl acrylate or an acrylamide or methacrylamide, and up to 85 weight percent of one or more ethylenically unsaturated polymerizable crosslinkable monomers.
26. A multilayer element for the determination of glucose in whole blood, said element consisting essentially of a support having thereon, in order and in fluid contact, a registration layer and a reagent/spreading layer, said spreading/reagent layer having a void volume and average pore size effective to accommodate whole blood, and containing an interactive composition necessary for said glucose determination, said interactive composition comprising glucose oxidase, a substance having peroxidative activity, an aminoantipyrine and a color-forming coupler which, upon the interaction of said composition with glucose, provides a dye which can be spectrophotometrically detected at a wavelength greater than about 600 nm.
27. The element of claim 26 wherein said interactive composition comprises peroxidase, 4-aminoantipyrine and a buffer which provides a pH of from about 4 to about 7 under conditions of use.
28. The element of claim 26 wherein said color-forming coupler is a toluidine compound or a substituted aniline compound.
29. The element of claim 28 wherein said interactive composition comprises glucose oxidase, peroxidase, 4-aminoantipyrine, 3,3-dimethylglutaric acid and 8-anilino-1-naphthalenesulfonic acid; and said reagent/spreading layer comprises a particulate structure comprising (i) a plurality of poly(vinyltoluene-co-p-t-butylstyrene-co-methacrylic acid) (61:37:2 weight ratio) particles having a substantially uniform particle size of from about 40 to about 60 microns; and (ii) an adhesive, in an amount less than about 10 percent by weight of said particles, comprising poly(n-butyl acrylate-co-styrene-co-2-acrylamido-2-methylpropane sulfonic acid) (70:20:10 weight ratio).
30. A multizone element for the determination of an analyte in whole blood, said element consisting of a support having thereon, in order and in fluid contact, a registration zone, a subbing zone and a reagent/spreading zone, said reagent/spreading zone having a void volume and average pore size effective to accommodate whole blood, and containing an interactive composition necessary for said determination, said interactive composition comprising a substance having peroxidative activity, and capable of providing, upon interaction with said analyte, a dye which can be spectrophotometrically detected at a wavelength greater than about 600 nm.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/546,694 US4637978A (en) | 1983-10-28 | 1983-10-28 | Assay for analysis of whole blood |
US546,694 | 1983-10-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1212602A true CA1212602A (en) | 1986-10-14 |
Family
ID=24181587
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000445619A Expired CA1212602A (en) | 1983-10-28 | 1984-01-19 | Assay for analysis of whole blood |
Country Status (5)
Country | Link |
---|---|
US (1) | US4637978A (en) |
EP (1) | EP0140337B1 (en) |
JP (1) | JPS60111960A (en) |
CA (1) | CA1212602A (en) |
DE (1) | DE3477841D1 (en) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62120993A (en) * | 1985-11-06 | 1987-06-02 | ファナック株式会社 | Dustproof structure of industrial robot |
US5501949A (en) * | 1985-12-10 | 1996-03-26 | Murex Diagnostics Corporation | Particle bound binding component immunoassay |
US4923798A (en) * | 1986-03-26 | 1990-05-08 | Synbiotics Corporation | Saliva test for feline leukemia virus |
US4935346A (en) | 1986-08-13 | 1990-06-19 | Lifescan, Inc. | Minimum procedure system for the determination of analytes |
US4786589A (en) * | 1986-08-18 | 1988-11-22 | Huntington Medical Research Institute | Immunoassay utilizing formazan-prelabeled reactants |
US4790979A (en) * | 1986-08-29 | 1988-12-13 | Technimed Corporation | Test strip and fixture |
US4939096A (en) * | 1986-09-10 | 1990-07-03 | Idexx, Corp. | Method and apparatus for assaying whole blood |
US4774192A (en) * | 1987-01-28 | 1988-09-27 | Technimed Corporation | A dry reagent delivery system with membrane having porosity gradient |
JPH0623759B2 (en) * | 1987-07-08 | 1994-03-30 | 富士写真フイルム株式会社 | Whole blood analysis element |
US5215716A (en) * | 1987-12-28 | 1993-06-01 | Fuji Photo Film Co., Ltd. | Integral multilayer analytical element |
US4876207A (en) * | 1988-02-16 | 1989-10-24 | Eastman Kodak Company | Compositions for the detection of high levels of hydrogen peroxide |
US5620845A (en) * | 1988-06-06 | 1997-04-15 | Ampcor, Inc. | Immunoassay diagnostic kit |
US4994238A (en) * | 1988-06-09 | 1991-02-19 | Daffern George M | Constant volume chemical analysis test device |
US5096809A (en) * | 1988-07-25 | 1992-03-17 | Pacific Biotech, Inc. | Whole blood assays using porous membrane support devices |
US5260221A (en) * | 1989-03-16 | 1993-11-09 | Ramel Urs A | Sample pad assay initiation device |
US5264180A (en) * | 1989-03-16 | 1993-11-23 | Chemtrak, Inc. | Mobile reagents in an analyte assay in a self-contained apparatus |
SE466157B (en) | 1989-04-25 | 1992-01-07 | Migrata Uk Ltd | DETERMINED TO DETERMINE THE GLUCOSE CONTENT OF WHOLE BLOOD AND DISPOSABLE BEFORE THIS |
US5087556A (en) * | 1989-05-17 | 1992-02-11 | Actimed Laboratories, Inc. | Method for quantitative analysis of body fluid constituents |
US5312759A (en) * | 1989-12-20 | 1994-05-17 | Iatron Laboratories, Inc. | Method for measurement of fructosamines using 1,2-quinones |
US5081042A (en) * | 1990-03-20 | 1992-01-14 | Minnesota Mining And Manufacturing Company | Ionic component sensor and method for making and using same |
US5081041A (en) * | 1990-04-03 | 1992-01-14 | Minnesota Mining And Manufacturing Company | Ionic component sensor and method for making and using same |
US5470757A (en) * | 1991-06-25 | 1995-11-28 | Minnesota Mining And Manufacturing Company | Spectroscopic sample holder and method for using same |
US5286450A (en) * | 1992-06-01 | 1994-02-15 | Eastman Kodak Company | Bilirubin assay using crosslinkable polymers |
US5354692A (en) * | 1992-09-08 | 1994-10-11 | Pacific Biotech, Inc. | Analyte detection device including a hydrophobic barrier for improved fluid flow |
US5837546A (en) * | 1993-08-24 | 1998-11-17 | Metrika, Inc. | Electronic assay device and method |
US5770389A (en) * | 1993-09-27 | 1998-06-23 | Abbott Laboratories | Apparatus and method for determining the quanity of an analyte in a biological sample by means of transmission photometry |
AU692845B2 (en) * | 1994-03-04 | 1998-06-18 | Memtec America Corporation | Large pore synthetic polymer membranes |
US5755231A (en) * | 1995-05-17 | 1998-05-26 | Plus Bio, Inc. | Test strip including integral specimen flow retarding structure |
US7635597B2 (en) | 1995-08-09 | 2009-12-22 | Bayer Healthcare Llc | Dry reagent particle assay and device having multiple test zones and method therefor |
US6638415B1 (en) | 1995-11-16 | 2003-10-28 | Lifescan, Inc. | Antioxidant sensor |
US5981294A (en) * | 1995-11-29 | 1999-11-09 | Metrika, Inc. | Device for blood separation in a diagnostic device |
US7828749B2 (en) | 1996-05-17 | 2010-11-09 | Roche Diagnostics Operations, Inc. | Blood and interstitial fluid sampling device |
EP1579814A3 (en) * | 1996-05-17 | 2006-06-14 | Roche Diagnostics Operations, Inc. | Methods and apparatus for sampling and analyzing body fluid |
US20020010406A1 (en) | 1996-05-17 | 2002-01-24 | Douglas Joel S. | Methods and apparatus for expressing body fluid from an incision |
US7235056B2 (en) * | 1996-05-17 | 2007-06-26 | Amira Medical | Body fluid sampling device and methods of use |
EP2290362B1 (en) | 1996-10-30 | 2013-01-23 | F. Hoffmann-La Roche AG | Synchronized analyte testing system |
US6632349B1 (en) * | 1996-11-15 | 2003-10-14 | Lifescan, Inc. | Hemoglobin sensor |
US5879951A (en) * | 1997-01-29 | 1999-03-09 | Smithkline Diagnostics, Inc. | Opposable-element assay device employing unidirectional flow |
US20050101032A1 (en) * | 1997-02-10 | 2005-05-12 | Metrika, Inc. | Assay device, composition, and method of optimizing assay sensitivity |
US5885839A (en) * | 1997-04-15 | 1999-03-23 | Lxn Corporation | Methods of determining initiation and variable end points for measuring a chemical reaction |
US5939252A (en) * | 1997-05-09 | 1999-08-17 | Lennon; Donald J. | Detachable-element assay device |
US5948695A (en) * | 1997-06-17 | 1999-09-07 | Mercury Diagnostics, Inc. | Device for determination of an analyte in a body fluid |
AUPO855897A0 (en) * | 1997-08-13 | 1997-09-04 | Usf Filtration And Separations Group Inc. | Automatic analysing apparatus II |
US6121050A (en) * | 1997-08-29 | 2000-09-19 | Han; Chi-Neng Arthur | Analyte detection systems |
US6706000B2 (en) * | 1997-11-21 | 2004-03-16 | Amira Medical | Methods and apparatus for expressing body fluid from an incision |
US20060019404A1 (en) * | 1998-05-06 | 2006-01-26 | Blatt Joel M | Quantitative assay with extended dynamic range |
US6074881A (en) * | 1998-08-03 | 2000-06-13 | Bayer Corporation | Method for the prevention of hemoglobin interference in reagent systems for measuring peroxidase activity |
US6551842B1 (en) | 1999-03-26 | 2003-04-22 | Idexx Laboratories, Inc. | Method and device for detecting analytes in fluids |
US6602719B1 (en) | 1999-03-26 | 2003-08-05 | Idexx Laboratories, Inc. | Method and device for detecting analytes in fluids |
US6511814B1 (en) | 1999-03-26 | 2003-01-28 | Idexx Laboratories, Inc. | Method and device for detecting analytes in fluids |
US6458326B1 (en) | 1999-11-24 | 2002-10-01 | Home Diagnostics, Inc. | Protective test strip platform |
RU2278612C2 (en) | 2000-07-14 | 2006-06-27 | Лайфскен, Инк. | Immune sensor |
US6525330B2 (en) | 2001-02-28 | 2003-02-25 | Home Diagnostics, Inc. | Method of strip insertion detection |
US6541266B2 (en) | 2001-02-28 | 2003-04-01 | Home Diagnostics, Inc. | Method for determining concentration of an analyte in a test strip |
US6562625B2 (en) * | 2001-02-28 | 2003-05-13 | Home Diagnostics, Inc. | Distinguishing test types through spectral analysis |
US20020188223A1 (en) | 2001-06-08 | 2002-12-12 | Edward Perez | Devices and methods for the expression of bodily fluids from an incision |
US20030055360A1 (en) * | 2001-09-05 | 2003-03-20 | Zeleznik Matthew A. | Minimally invasive sensing system for measuring rigidity of anatomical matter |
CA2461370A1 (en) | 2001-09-26 | 2003-05-15 | F. Hoffmann-La Roche Ag | Method and apparatus for sampling bodily fluid |
US6997343B2 (en) | 2001-11-14 | 2006-02-14 | Hypoguard Limited | Sensor dispensing device |
US20030111357A1 (en) * | 2001-12-13 | 2003-06-19 | Black Murdo M. | Test meter calibration |
US20030169426A1 (en) * | 2002-03-08 | 2003-09-11 | Peterson Timothy A. | Test member orientation |
US20030180814A1 (en) * | 2002-03-21 | 2003-09-25 | Alastair Hodges | Direct immunosensor assay |
US20060134713A1 (en) * | 2002-03-21 | 2006-06-22 | Lifescan, Inc. | Biosensor apparatus and methods of use |
US7250095B2 (en) * | 2002-07-11 | 2007-07-31 | Hypoguard Limited | Enzyme electrodes and method of manufacture |
US7264139B2 (en) * | 2003-01-14 | 2007-09-04 | Hypoguard Limited | Sensor dispensing device |
US20080149524A1 (en) * | 2003-03-27 | 2008-06-26 | Rademaker William B | Food containers including dental cleaning devices and other personal care items |
US20050150763A1 (en) * | 2004-01-09 | 2005-07-14 | Butters Colin W. | Biosensor and method of manufacture |
US7150995B2 (en) * | 2004-01-16 | 2006-12-19 | Metrika, Inc. | Methods and systems for point of care bodily fluid analysis |
US20050227370A1 (en) * | 2004-03-08 | 2005-10-13 | Ramel Urs A | Body fluid analyte meter & cartridge system for performing combined general chemical and specific binding assays |
US20080057528A1 (en) * | 2006-08-30 | 2008-03-06 | Kimberly-Clark Worldwide, Inc. | Detection of hydrogen peroxide released by enzyme-catalyzed oxidation of an analyte |
LU100795B1 (en) * | 2018-05-14 | 2019-11-14 | Diatron MI PLC | Immunoassay for whole blood samples |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3092465A (en) * | 1960-03-25 | 1963-06-04 | Miles Lab | Diagnostic test device for blood sugar |
US3992158A (en) * | 1973-08-16 | 1976-11-16 | Eastman Kodak Company | Integral analytical element |
US3983005A (en) * | 1974-03-25 | 1976-09-28 | Eastman Kodak Company | Integral element for the analysis of cholesterol |
US4042335A (en) * | 1975-07-23 | 1977-08-16 | Eastman Kodak Company | Integral element for analysis of liquids |
US4057394A (en) * | 1976-05-24 | 1977-11-08 | Miles Laboratories, Inc. | Test device and method for determining blood hemoglobin |
CA1095819A (en) * | 1977-01-14 | 1981-02-17 | Eastman Kodak Company | Element for analysis of liquids |
US4098574A (en) * | 1977-08-01 | 1978-07-04 | Eastman Kodak Company | Glucose detection system free from fluoride-ion interference |
US4258001A (en) * | 1978-12-27 | 1981-03-24 | Eastman Kodak Company | Element, structure and method for the analysis or transport of liquids |
US4381921A (en) * | 1978-12-27 | 1983-05-03 | Eastman Kodak Company | Element, structure and method for the analysis or transport of liquids |
DE2910134A1 (en) * | 1979-03-15 | 1980-09-25 | Boehringer Mannheim Gmbh | DIAGNOSTIC AGENT FOR DETECTING COMPONENTS OF BODY LIQUIDS |
JPS55164356A (en) * | 1979-06-08 | 1980-12-22 | Fuji Photo Film Co Ltd | Multi-layer analysis sheet for liquid sample analysis |
JPS6033479B2 (en) * | 1980-07-30 | 1985-08-02 | 協和醗酵工業株式会社 | Method for quantifying hydrogen peroxide |
JPS5794653A (en) * | 1980-12-04 | 1982-06-12 | Konishiroku Photo Ind Co Ltd | Element for analysis |
JPS5794655A (en) * | 1980-12-04 | 1982-06-12 | Konishiroku Photo Ind Co Ltd | Element for analysis |
JPS57101760A (en) * | 1980-12-17 | 1982-06-24 | Konishiroku Photo Ind Co Ltd | Analyzing element |
JPS57101761A (en) * | 1980-12-17 | 1982-06-24 | Konishiroku Photo Ind Co Ltd | Analyzing element |
JPS5870163A (en) * | 1981-09-29 | 1983-04-26 | Konishiroku Photo Ind Co Ltd | Analysis element |
-
1983
- 1983-10-28 US US06/546,694 patent/US4637978A/en not_active Expired - Fee Related
-
1984
- 1984-01-19 CA CA000445619A patent/CA1212602A/en not_active Expired
- 1984-10-25 DE DE8484112835T patent/DE3477841D1/en not_active Expired
- 1984-10-25 EP EP84112835A patent/EP0140337B1/en not_active Expired
- 1984-10-26 JP JP59224231A patent/JPS60111960A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS60111960A (en) | 1985-06-18 |
EP0140337A3 (en) | 1985-07-10 |
EP0140337B1 (en) | 1989-04-19 |
DE3477841D1 (en) | 1989-05-24 |
JPH0454902B2 (en) | 1992-09-01 |
US4637978A (en) | 1987-01-20 |
EP0140337A2 (en) | 1985-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1212602A (en) | Assay for analysis of whole blood | |
EP0013156B1 (en) | Particulate structure and element for analysis or transport of a liquid and method of making said element | |
CA1271706A (en) | Heterogeneous immunoassay utilizing horizontal separation in an analytical element | |
US4430436A (en) | Analytical element and method of use | |
US4069017A (en) | Colorimetric assay for bilirubin | |
US4966856A (en) | Analytical element and the analytical method using the element | |
AU722471B2 (en) | Blood glucose strip having reduced sensitivity to hematocrit | |
US4381921A (en) | Element, structure and method for the analysis or transport of liquids | |
US4975366A (en) | Multi-layered element for quantititative analysis of immuno reactant | |
EP0176357B1 (en) | Analytical element and method for colorimetric determination of total cholesterol | |
US4357363A (en) | Element, structure and method for the analysis or transport of liquids | |
US5569589A (en) | Immunoassay element and process and immunoassay | |
EP0134953B1 (en) | Multilayer analytical element | |
US4874692A (en) | Binder composition and analytical element having stabilized peroxidase in layer containing the composition | |
EP0169055B1 (en) | Polymeric single layer analytical element | |
US4604347A (en) | Analytical element for dry analysis | |
EP0579250A2 (en) | Homogeneous immunoassay, enzyme-labelled antibody and element | |
JPS61177997A (en) | Analytical element | |
EP0253581A1 (en) | Analytical element having water-soluble polymers and determinations using same | |
EP0884591B1 (en) | Immunoassay element | |
USH600H (en) | Whole blood analytical element and method of analyzing whole blood using the same | |
US5506116A (en) | Method and element for assay of catechol and catechol generating substances | |
JPH0521013Y2 (en) | ||
JP2565788B2 (en) | Method for quantifying high-density lipoprotein cholesterol | |
JPH04128655A (en) | Immunological analytical element and method therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |